UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

Commission file number 001-37693

AVEXIS, INC.

State of Delaware		90-1038273
Incorporated under the Laws of the		I.R.S. Employer Identification No.

2275 Half Day Rd, Suite 200

Bannockburn, Illinois 60015

(847) 572-8280

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Name of each exchange on which registered
Common Stock, $0.0001, par value		The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Exchange Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulations S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x		Accelerated filer o
Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)		Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based on the closing price of the registrant’s common stock for the last business day of the registrant’s most recently completed second fiscal quarter: $2,265,553,538

As of April 27, 2018, 36,816,476 shares of common stock, $0.0001 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

EXPLANATORY NOTE

AveXis, Inc. (“AveXis,” “we,” “us,” “our” or the “Company”) is filing this Amendment No. 1 (the “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (File Number 001-37693) (the “Original Form 10-K Filing”), as filed by the Company with the Securities and Exchange Commission (the “SEC”) on February 28, 2018, solely for the purpose of amending Items 10 through 14 in Part III and Item 15 in Part IV. The information in Part III was previously omitted from the Original Form 10-K Filing in reliance on General Instruction G(3) to Form 10-K, which provides that registrants may incorporate by reference certain information from a definitive proxy statement filed with the SEC within 120 days after the end of the fiscal year covered by the report. On April 6, 2018, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Novartis AG, a company organized under the laws of Switzerland (“Parent”), and Novartis AM Merger Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and, as a result, we do not expect to conduct a 2018 annual meeting of stockholders. See “Agreement and Plan of Merger” for a description of the Merger Agreement.

In accordance with, among other things, Rule 12b-15 under the Securities Exchange Act of 1934, as amended, each item of the Original Form 10-K Filing that is amended by the Amendment is also restated in its entirety, and the Amendment is accompanied by currently dated certifications on Exhibit 31.3 by the Company’s Chief Executive Officer and Exhibit 31.4 by the Company’s Chief Financial Officer (because no financial statements have been included in the Amendment and the Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted). The Amendment is being filed to: (i) delete the reference on the cover of the Original Form 10-K Filing to the incorporation by reference information from the Company’s definitive proxy statement, (ii) revise Part III, Items 10 through 14 of the Original Form 10-K Filing to include information previously omitted from the Original Form 10-K Filing and (iii) revise the Exhibit Index of the Original Form 10-K Filing to reflect the filing of the new certifications.

No attempt has been made in the Amendment to modify or update the other disclosures presented in the Original Form 10-K Filing. The Amendment does not reflect events occurring after the filing of the Original Form 10-K Filing or modify or update those disclosures that may be affected by subsequent events, other than as expressly indicated in the Amendment. Accordingly, the Amendment should be read in conjunction with the Original Form 10-K Filing and the Company’s other filings with the SEC.

Agreement and Plan of Merger

On April 6, 2018, the Company entered into the Merger Agreement with Parent and Purchaser, pursuant to which, and upon the terms and subject to the conditions described therein, on April 17, 2018, Purchaser commenced a cash tender offer (the “Offer”) to acquire all of the outstanding shares of the Company’s common stock at a purchase price of $218.00 per share (such price, as it may be increased as described in the following sentence, the “Offer Price”), net to the seller in cash, without interest, subject to any required withholding of taxes. In the event Parent elects to extend the Outside Date (as defined in the Merger Agreement) in accordance with the terms of the Merger Agreement, the Offer Price will be increased to $225.00 per share, net to the seller in cash, without interest, subject to any required withholding of taxes. The Offer will expire at 12:00 Midnight, New York City time, at the end of the day on Monday, May 14, 2018 (unless the Offer is extended).

The obligation of Purchaser to purchase shares of the Company’s common stock tendered in the Offer is subject to customary closing conditions, including (i) shares of the Company’s common stock having been validly tendered and not withdrawn that represent at least a majority of the total number of shares of the Company’s common stock then-outstanding on a fully diluted basis, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), without the imposition of a Burdensome Condition (as defined in the Merger Agreement), (iii) the absence of injunctions or other legal restraints preventing the consummation of the Offer or the Merger, as defined below, or imposing a Burdensome

Condition and (iv) certain other conditions set forth in Exhibit A to the Merger Agreement. The consummation of the Offer is not subject to any financing condition.

Following the completion of the Offer, subject to the satisfaction or waiver of certain customary conditions set forth in the Merger Agreement, Purchaser will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”), pursuant to the procedure provided for under Section 251(h) of the Delaware General Corporation Law (the “DGCL”), without any stockholder approvals. The Merger will be effected as soon as practicable following the time of purchase by Purchaser of shares of the Company’s common stock validly tendered and not withdrawn in the Offer. At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of the Company’s common stock (other than shares owned by (i) the Company, any subsidiary of the Company, Parent, Purchaser and any other subsidiary of Parent and (ii) stockholders of the Company who have validly exercised their statutory rights of appraisal under the DGCL) will be converted into the right to receive the Offer Price, in cash, without interest, subject to any required withholding of taxes.

Until the earlier of the termination of the Merger Agreement and the Effective Time, the Company has agreed to operate its business in the ordinary course and has agreed to certain other operating covenants, as set forth more fully in the Merger Agreement. The Merger Agreement includes customary termination provisions for both the Company and Parent and provides that, in connection with the termination of the Merger Agreement under specified circumstances, including termination by the Company to accept a Superior Company Proposal (as defined in the Merger Agreement), the Company will be required to pay a fee equal to $284 million. The Merger Agreement also provides that, in connection with the termination of the Merger Agreement under specified antitrust related circumstances, Parent will be required to pay to the Company a “reverse termination fee” equal to $437 million, which fee increases in the event Parent elects to extend the Outside Date in accordance with the terms of the Merger Agreement.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The names of our directors and executive officers, their ages as of March 15, 2018 and certain other information about them are set forth below. There are no family relationships among any of our directors or executive officers.

Executive Officers

Sean P. Nolan, age 50, has served as our President and Chief Executive Officer and as a member of our Board of Directors since June 2015. Prior to joining us, from February 2013 to April 2015, he was the chief business officer of InterMune, Inc., a biotechnology company later acquired by Roche Holding Ltd. While at InterMune, Mr. Nolan led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development and global manufacturing and supply chain. Mr. Nolan was also responsible for planning and executing the U.S. launch of InterMune’s treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no other approved treatments. Mr. Nolan served as chief commercial officer at Reata Pharmaceuticals, Inc. from August 2011 to December 2012, where he led the market strategy development and commercial planning for Reata Pharmaceuticals’ first in-class product pipeline. From September 2004 to November 2010, Mr. Nolan worked at Ovation Pharmaceuticals, Inc., a company focused on orphan neurology diseases. He held numerous management positions during that period including president of Lundbeck Inc., the U.S. affiliate. Ovation Pharmaceuticals was acquired by H. Lundbeck A/S in March 2009 for $900 million. Mr. Nolan holds a B.A. in biology from John Carroll University. Mr. Nolan currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. Our Board of Directors believes that Mr. Nolan is qualified to serve as a director based on his role as our principal executive officer and his over 27 years of broad leadership and management experience in the biopharmaceutical industry.

Phillip B. Donenberg, age 57, has served as our Senior Vice President and Chief Financial Officer since October 2017. He previously served as our Vice President, Corporate Controller from September 2016 to October 2017. He was the chief financial officer of RestorGenex Corporation from May 2014 to January 2016, when RestorGenex merged with Diffusion Pharmaceuticals LLC and served as the merged company’s consultant CFO until September 2016, and the chief financial officer of 7wire Ventures LLC from September 2013 to May 2014. Prior to that time, Mr. Donenberg served as the chief financial officer of BioSante Pharmaceuticals, Inc. from July 1998 to June 2013, when BioSante merged with ANIP Pharmaceuticals, Inc. Mr. Donenberg holds a B.S. in Accountancy from the University of Illinois Champaign-Urbana College of Business and is a Certified Public Accountant.

Michael B. Johannesen, age 52, has served as our Senior Vice President, General Counsel and Chief Compliance Officer since July 2016. Prior to joining us, from May 2004 to April 2016, he served in various positions, including as vice president, associate general counsel and assistant secretary of Hospira, Inc., where he was responsible for the commercial and compliance functions of Hospira’s legal department. He previously served in the legal departments of Abbott Laboratories and Whirlpool Corporation, and as an associate at the law firm of Winston & Strawn. Mr. Johannesen received a B.A. in political science and public administration from the University of Illinois and a Juris Doctor from the University of Michigan Law School.

Brian K. Kaspar, age 44, has served as our Senior Vice President and Chief Scientific Officer since June 2015, a position he held from June 2015 to December 2015 in connection with his scientific advisory consulting services, and thereafter as our employee. Dr. Kaspar provided scientific advisory consulting services to the Company from January 2014 to December 2015. He has served as a member of our Board of Directors since October 2013. Dr. Kaspar served from August 2004 to September 2017 as a principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and professor in the department of pediatrics and department of neuroscience at The Ohio State University College of Medicine, where his research focused on basic and translational studies related to neurological and neuromuscular disorders. In 2013, Dr. Kaspar was named Fellow of the American Association for the Advancement of Science. In September 2011, Dr. Kaspar co-founded Milo Biotechnology LLC, which develops muscle mass loss treatment and therapies. Dr. Kaspar currently serves as a consultant to Milo Biotechnology LLC in connection with the continuation of its clinical trials. Dr. Kaspar has published more than 100 scientific articles in peer-reviewed journals. Dr. Kaspar holds a B.S. from the University of

Illinois and a Ph.D. from the University of California, San Diego and has done post-doctoral training at the University of California, San Diego and the Salk Institute for Biological Studies. Our Board of Directors believes that Dr. Kaspar is qualified to serve as a director based upon his extensive scientific, operating, regulatory and medical experience, including 20 years of gene therapy experience.

Andrew F. Knudten, age 50, has served as our Senior Vice President, Technical Operations and Chief Technical Officer since March 2018. He previously served as Senior Vice President, Manufacturing and Supply Chain from September 2015 to March 2018. Previously, Mr. Knudten served as vice president of operations and vice president of active pharmaceutical ingredient operations at Hospira, Inc. from March 2012 to September 2015, where he had overall global responsibility for the company’s API business. Mr. Knudten also previously served as global head of contract manufacturing and strategy for Novartis Vaccines and Diagnostics, Inc. from February 2009 to March 2012, and as vice president of manufacturing at CoDa Therapeutics, Inc. from September 2007 to February 2009. From 1994 to 2007, he served in various research, product development, finance and operations roles at Amgen Inc., supporting the development of numerous pipeline products and more than five eventual commercial products now being marketed by Amgen. Mr. Knudten earned a B.S. in biology and health from Concordia University, an M.S. in cell biology from University of Nebraska, Lincoln and an M.B.A. from the Anderson School at the University of California, Los Angeles.

James J. L’Italien, age 65, has served as our Senior Vice President and Chief Regulatory and Quality Officer since July 2015. Before joining us, since 2012, Dr. L’Italien served as senior vice president of regulatory affairs and quality assurance for InterMune, Inc. While at InterMune, he oversaw all global regulatory affairs and quality assurance activities in support of its commercial- and development-stage pharmaceutical programs, including the regulatory process for Esbriet®, which was granted a breakthrough designation by the U.S. Food and Drug Administration. Prior to that, Dr. L’Italien served as vice president of regulatory affairs and quality assurance for Geron Corporation from 2009 until 2012, where he supported development-stage programs in oncology and stem cell therapy. Before joining Geron, he served as senior vice president of regulatory affairs and quality assurance for Somaxon Pharmaceuticals, Inc. from 2007 to 2009, and held the global position of senior vice president of regulatory affairs and compliance at Ligand Pharmaceuticals, Inc. from 2002 to 2007. Dr. L’Italien received a B.S. in chemistry from Merrimack College and a Ph.D. in protein biochemistry from Boston University.

Raken B. Modi, age 49, has served as our Senior Vice President, Chief Business Officer since February 2017. Prior to joining us, Mr. Modi served as chief business officer for Catabasis Pharmaceuticals, Inc. from January 2015 to February 2017. Prior to that, Mr. Modi worked from July 2013 to January 2015 as the senior vice president of global marketing at InterMune, Inc., which was acquired by Hoffman-La Roche AG in 2014. From February 2008 to July 2013, Mr. Modi worked at MedImmune, LLC, a wholly-owned biologics research and development subsidiary of AstraZenca plc, in positions of increasing responsibility, ultimately as the vice president of corporate strategy and portfolio management. From January 2002 to February 2008, Mr. Modi worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Incorporated), a wholly-owned biotechnology subsidiary of Johnson & Johnson, serving in several positions, including as associate director of global market development. Mr. Modi received a B.S. in pharmacy from the University of Iowa and an M.B.A. from The Wharton School of the University of Pennsylvania.

Sukumar Nagendran, age 51, has served as our Senior Vice President and Chief Medical Officer since September 2015. Prior to joining us, from March 2013 to September 2015, he served as vice president, head of medical affairs of U.S. and international business for Quest Diagnostics Inc., the largest lab/diagnostics provider in the world. From October 2012 to February 2013, Dr. Nagendran served as the vice president, head of medical affairs for Reata Pharmaceuticals, Inc., a biotechnology company. He also previously served in a number of leadership positions at Daiichi Sankyo Company from March 2008 until October 2012, including head of new products, metabolism, oncology, biometrics and clinical operations for medical affairs. In February 2009, Dr. Nagendran filed a petition for personal bankruptcy under Chapter 7 of the federal bankruptcy laws, which was subsequently discharged in October 2009. Dr. Nagendran received a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota and is a Mayo Alumni Laureate.

R.A. Session II, age 39, has served as our Senior Vice President, Corporate Strategy and Business Development since December 2017. He previously served as our Senior Vice President, Corporate Strategy and Project Management from March 2017 to December 2017. Prior to joining us, Mr. Session served in various roles for PTC Therapeutics, Inc. from June 2013 to March 2017, most recently as the vice president of commercial development. He previously served in various roles at Reata Pharmaceuticals, Inc. from July 2012 to June 2013, most recently as the senior director of strategic planning and finance. From January 2007 to August 2008, Mr. Session worked at AstraZeneca Pharmaceuticals as senior manager of commercial portfolio and post deal analytics in the managed markets group. He began his career in the pharmaceutical division of Johnson & Johnson, where he served in several positions including as a senior financial analyst in the strategic business group. Mr. Session is a member of the Kauffman Fellows Society. Mr. Session received a B.S.B.A. in finance from the University of North Carolina at Charlotte, a M.S.F. in finance from Texas A&M University-Commerce and an M.B.A. from Texas A&M University-Commerce.

Lori J. Smith, age 54, has served as our Senior Vice President, Chief Human Resources Officer since April 2017. Prior to joining us, Ms. Smith served as an independent business consultant, where she provided strategic guidance to executives in multiple disciplines, since February 2007. She previously served in various roles for Takeda Pharmaceuticals North America, Inc., most recently as the senior vice president, human resources and administration, from February 1999 to January 2007. Ms. Smith received a B.S. in psychology from the University of Wisconsin-La Crosse.

Non-Employee Directors

Daniel Welch, age 60, has served as a member, and the chairman, of our Board of Directors since January 2016. He currently serves as a consultant at Sofinnova Ventures, where he previously served as an executive partner from January 2015 to January 2018. Mr. Welch previously served as the president and chief executive officer of InterMune, Inc. from September 2003 to September 2014, and he served as the chairman of the board of directors of InterMune from May 2007 to September 2014. From August 2002 to January 2003, Mr. Welch served as chairman and chief executive officer of Triangle Pharmaceuticals, Inc. He currently serves on the boards of directors of Seattle Genetics, Inc., Ultragenyx Pharmaceutical Inc., where he also serves as chairman, and Intercept Pharmaceuticals, Inc., and previously served on the board of directors of Hyperion Therapeutics, Inc. from 2012 to 2015. Mr. Welch received a B.S. from the University of Miami and an M.B.A from the University of North Carolina. Our Board of Directors believes that Mr. Welch should serve as chairman based on his operational and strategic expertise and his extensive experience in leading companies from clinical-stage drug development to large-scale global commercialization.

Terrence C. Kearney, age 63, has served as a member of our Board of Directors since January 2016. Most recently, Mr. Kearney served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication management delivery company, from 2006 until his retirement in 2011. From 2004 to 2006, he served as Hospira’s Senior Vice President, Finance, and Chief Financial Officer. He currently serves as a member of the board of directors of Acceleron Pharma, Inc. and Vertex Pharmaceuticals Incorporated, and he previously served as a member of the board of directors of Innoviva, Inc., formerly known as Theravance, Inc. from October 2014 to April 2016. Mr. Kearney received a B.S. in biology from the University of Illinois and an M.B.A. from the University of Denver. Our Board of Directors believes that Mr. Kearney should serve as a director based on his extensive experience in the biotechnology industry as both an executive officer and a director, as well as his financial expertise.

Bong Koh, age 45, has served as a member of our Board of Directors since June 2015. Since 2009, Dr. Koh has been a partner at Venrock, a venture capital firm where he manages Venrock’s public and cross-over biotechnology fund. Dr. Koh earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School. Our Board of Directors believes that Dr. Koh should serve as a director based on his extensive experience in the biotechnology industry providing leadership in biotechnology investments.

Paul B. Manning, age 62, has served as a member of our Board of Directors since April 2014. Mr. Manning is the president and chief executive officer of PBM Capital Group, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products, LLC in 1997, a producer of infant formula and baby food, which was sold to Perrigo

Corporation in 2010. Mr. Manning is the chairman of Dova Pharmaceuticals, Inc., and was previously on the board of directors of Perrigo Corporation and Concordia Healthcare Corp. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our Board of Directors believes that Mr. Manning should serve as a director based on his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.

Joao Siffert, age 54, has served as a member of our Board of Directors since May 2017. Since May 2016, Dr. Siffert has served as the chief medical officer and head of development at Nestlé Health Science S.A. Previously, Dr. Siffert was executive vice president, research & development and chief medical officer of Avanir Pharmaceuticals, Inc., a position he held from March 2015 to April 2016. Prior to that, he served in various roles at Avanir, including as senior vice president, research and development and chief medical officer from February 2014 to March 2015 and senior vice president, research and development and chief science officer from August 2011 to February 2014 and as chief medical officer of Ceregene, Inc. from September 2007 to August 2011. Dr. Siffert served on the board of Directors of Alcobra Pharmaceuticals from July 2015 to July 2017. Dr. Siffert completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of Neurology and Psychiatry in 1996. He holds an M.D. degree from the University of São Paulo School of Medicine as well as an M.B.A. degree from Columbia University Business School. Our Board of Directors believes that Dr. Siffert should serve as a director based on his experience in orphan drug development and regulatory expertise in both the United States and Europe.

Frank Verwiel, age 55, has served as a member of our Board of Directors since December 2015. Dr. Verwiel was the President and Chief Executive Officer of Aptalis Pharma Inc. from 2005 to 2014, where he also served on the board of directors. He currently serves as a member of the board of directors of Achillion Pharmaceuticals, Inc., Bavarian Nordic A/S, Intellia Inc. and ObsEva SA, where he serves as chairman. Dr. Verwiel previously served on the board of directors of InterMune, Inc. from 2012 to 2014. Dr. Verwiel was also a director of the Biotechnology Industry Organization. Dr. Verwiel received his M.D. from Erasmus University, Rotterdam and his M.B.A. from INSEAD. Our Board of Directors believes that Dr. Verwiel should serve as a director based on his scientific acumen and his over 25 years of strategic, operational and international experience in the pharmaceutical industry.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requires the Company’s directors and executive officers, and persons who own more than ten percent of a registered class of the Company’s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the fiscal year ended December 31, 2017, all Section 16(a) filing requirements applicable to its officers, directors and greater than ten percent beneficial owners were complied with.

Audit Committee and Audit Committee Financial Expert

The Audit Committee of the Board of Directors was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee the Company’s corporate accounting and financial reporting processes and audits of its financial statements. The Audit Committee is comprised of three directors: Messrs. Kearney and Manning and Dr. Verwiel, with Mr. Kearney serving as chair.

The Board of Directors reviews the Nasdaq Stock Market (“Nasdaq”) listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company’s Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards and Rule 10A-3 of the Exchange Act).

The Board of Directors has also determined that Mr. Kearney qualifies as an “audit committee financial expert,” as

defined in applicable SEC rules. The Board made a qualitative assessment of Mr. Kearney’s level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer for a public reporting company.

Stockholder Recommendations for Director Candidates

Historically, the Company has not provided a formal process related to stockholder communications with the Board. Nevertheless, every effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. The Company believes its responsiveness to stockholder communications to the Board has been excellent.

Code of Business Conduct and Ethics

The Company has adopted the AveXis, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available in the “Investors + Media” section of the Company’s website at www.avexis.com. If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website.

Item 11. Executive Compensation.

Compensation Discussion and Analysis

Executive Compensation

COMPENSATION DISCUSSION AND ANALYSIS

Overview

We are a clinical-stage gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate for the treatment of spinal muscular atrophy, or SMA. SMA is a severe neuromuscular disease characterized by the loss of motor neurons, leading to progressive muscle weakness and paralysis. The incidence of SMA is approximately one in 10,000 live births. SMA is generally divided into sub-categories termed SMA Type 1, 2, 3 and 4. We are conducting a pivotal clinical trial for AVXS-101 for the treatment of SMA Type 1, the leading genetic cause of infant mortality. We are also currently conducting a Phase 1 clinical trial of AVXS-101 for the treatment of SMA Type 2 and a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with SMA Types 1, 2 and 3. In addition to our ongoing clinical trials, we intend to expand our clinical development program of AVXS-101 for the treatment of SMA by initiating additional clinical trials to further evaluate AVXS-101, including in new patient populations. In addition to developing AVXS-101 to treat SMA, we plan to develop other novel treatments for two additional rare neurological monogenetic diseases, Rett syndrome and a genetic form of amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene, or genetic ALS.

We became a public company in February 2016, and we filed our 2017 proxy statement under the scaled-down reporting rules applicable to emerging growth companies. As of the close of calendar year 2017, we ceased to be an emerging growth company and, therefore, this year we have included additional detail regarding executive compensation that was previously not required, including: this Compensation Discussion and Analysis, additional compensation tables for “Grants of Plan-Based Awards,” “Option Exercises and Stock Vested,” and “Potential Payments upon Termination or Change in Control”.

This Compensation Discussion and Analysis provides an overview of the material components of our executive compensation program for the fiscal year ended December 31, 2017, for the Company’s Chief Executive Officer,

Chief Financial Officer and its three other most highly compensated executive officers at December 31, 2017, as well as the Company’s former Chief Financial Officer (the “named executive officers”), “named executive officers” who are listed below. This discussion and analysis is intended to assist you to understand the information provided in the compensation tables below and to provide additional context regarding our overall compensation program. In addition, we explain how and why our Board and Compensation Committee determined our compensation policies and specific compensation decisions for our named executive officers during and for fiscal year 2017.

Our named executive officers for the fiscal year ended December 31, 2017, are as follows:

· Sean P. Nolan, President and Chief Executive Officer

· Phillip B. Donenberg, Senior Vice President, Chief Financial Officer(1)

· James J. L’Italien, Ph.D., Senior Vice President, Chief Regulatory and Quality Officer

· Raken B. Modi, Senior Vice President, Chief Business Officer(2)

· Sukumar Nagendran, M.D., Senior Vice President, Chief Medical Officer

· Thomas J. Dee, former Senior Vice President, Chief Financial Officer(1)

(1) In October 2017, Mr. Dee resigned as our Senior Vice President and Chief Financial Officer and Mr. Donenberg was promoted from Vice President, Corporate Controller to Senior Vice President and Chief Financial Officer.

(2) Mr. Modi commenced employment with us as Senior Vice President, Chief Business Officer in February 2017.

Executive Summary

The important features of our executive compensation program include the following:

· We tie pay to performance. We structure a significant portion of our named executive officers’ compensation to be variable, at risk and tied directly to our measurable performance. For 2017, 92% of our Chief Executive Officer’s total reported compensation and a significant portion of our other continuing named executive officers’ total reported compensation was linked to performance, consisting of annual performance bonus earned and equity incentives awarded, as reported in the “Summary Compensation Table.”

*Reflects 2017 annual base salaries, performance bonuses earned and grant date fair values of equity awards, as reported in the Summary Compensation Table, for each of our NEOs other than Mr. Dee who terminated service in October 2017. The charts do not include Mr. Modi’s special signing bonus upon commencement of employment and “All Other Compensation”, as reported in the Summary Compensation Table (which represented less than 1% of total compensation for each individual).

· Our executive bonuses are dependent on meeting key corporate objectives. Our annual performance-based bonus opportunities for our named executive officers are dependent upon our achievement of annual corporate objectives established each year. No bonuses are guaranteed. We exceeded our specified corporate objectives for 2017 and each of our current named executive officers received performance bonuses in early 2018.

· We emphasize long-term equity incentives. Equity awards are an integral part of our executive compensation program, and comprise the primary “at-risk” portion of our named executive officer compensation package. We have historically granted equity awards in the form of stock options and we consider stock options performance-based because they provide value only if the market price of our stock increases, and if the executive officer continues in our employment over the option term. These awards strongly align our executive officers’ interests with those of our stockholders by providing a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to remain in our long-term employ. We have also recently introduced restricted stock units and performance-vesting restricted stock units as part of our executive compensation program for 2017 and 2018.

· Change in control payments are limited to double-trigger payments which require termination other than for cause or resignation for good reason in connection with a change of control to trigger payments. Equity awards granted on and after our IPO likewise provide only for double-trigger acceleration benefits.

· We do not provide our executive officers with any change in control excise tax gross ups.

· Our Compensation Committee has retained an independent third-party compensation consultant for guidance in making compensation decisions, who advises the Compensation Committee on market practices so that our Compensation Committee can regularly assess the Company’s individual and total compensation programs against those of peer companies, the general marketplace and other industry data points.

· We prohibit any and all hedging and pledging of Company stock.

Objectives, Philosophy and Elements of Compensation

The overall objectives of our executive compensation policies and programs are to:

· attract, retain and motivate superior executive talent;

· provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value, as well as to facilitate executive retention;

· align our executives’ interests with those of our stockholders;

· link pay to company performance; and

· offer pay opportunities that are competitive with the biopharmaceutical market in which we compete in order to recruit and retain top talent, while maintaining reasonable cost and dilution to our stockholders.

Our executive compensation program generally consists of, and is intended to strike a balance among, the following three principal components: base salary, annual performance-based bonuses and long-term incentive compensation. We also provide our executive officers with severance and change-in-control benefits, as well as other benefits available to all our employees, including retirement benefits under the Company’s 401(k) plan and participation in employee benefit plans. The following chart summarizes the three main elements of compensation, their objectives and key features.

Element of Compensation	Objectives	Key Features
Base Salary (fixed cash)	Provides financial stability and security through a fixed amount of cash for performing job responsibilities.	Generally reviewed annually and determined based on a number of factors (including individual performance, internal equity, retention, expected cost of living increases and the overall performance of our Company) and by reference to market data provided by our independent compensation consultant.

Performance Bonus (at-risk cash)	Motivates and rewards for attaining rigorous annual corporate performance goals that relate to our key business objectives and individual contributions.	Target bonus amounts, calculated as a percentage of base salary, are generally reviewed annually and determined based upon positions that have similar impact on the organization and competitive bonus opportunities in our market. Bonus opportunities are dependent upon achievement of specific corporate performance goals established at the beginning of the year and, except with respect to our Chief Executive Officer, individual performance objectives that relate to the officer’s role and expected contribution toward reaching our corporate goals. Actual bonus amounts earned are determined after the end of the year, based on achievement of the designated corporate performance objectives and, where applicable, individual performance objectives.

Long-Term Incentive (at-risk equity)	Motivates and rewards for long-term Company performance; aligns	Annual equity opportunities are generally reviewed and determined annually or as appropriate during the year for new hires,

executives’ interests with stockholder interests and changes in stockholder value. Attracts highly qualified executives and encourages their continued employment over the long-term.

promotions, or other special circumstances, such as to encourage retention, or as an incentive for significant achievement. Individual grants are determined based on a number of factors, including current corporate and individual performance, outstanding equity holdings and their retention value and total ownership, historical value of our stock, internal equity amongst executives and market data provided by our independent compensation consultant. Equity grants have historically been provided primarily in the form of stock options that typically vest over a four year period, although we began introducing restricted stock units in 2017 and our March 2018 equity grants included both stock options and restricted stock unit awards.

In evaluating our executive compensation policies and programs, as well as the short-term and long-term value of our executive compensation plans, we consider both the performance and skills of each of our executives, as well as the compensation paid to executives at similar companies with similar responsibilities. We focus on providing a competitive compensation package which provides significant short-term and long-term incentives for the achievement of measurable corporate objectives. We believe this approach provides an appropriate blend of short-term and long-term incentives to maximize stockholder value.

We do not have any formal policies for allocating compensation among salary, performance bonus awards and equity grants, short-term and long-term compensation or among cash and non-cash compensation. Instead, the Compensation Committee uses its judgment to establish a total compensation program for each named executive officer that is a mix of current, short-term and long-term incentive compensation, and cash and non-cash compensation, that it believes appropriate to achieve the goals of our executive compensation program and our corporate objectives. However, the Compensation Committee aims to structure a significant portion of the named executive officers’ total target compensation to be comprised of performance-based bonus opportunities and long-term equity awards, in order to align the executive officers’ incentives with the interests of our stockholders and our corporate objectives.

In making executive compensation decisions, the Compensation Committee generally considers each executive officer’s total target direct compensation, which consists of base salary, target bonus opportunity, which together with base salary we refer to as target cash compensation, and long-term equity awards (valued based on an approximation of grant date fair value).

How We Determine Executive Compensation

Role of the Compensation Committee and Executive Officers in Setting Executive Compensation

The Compensation Committee reviews and oversees our executive compensation policies, plans and programs and reviews and determines the compensation to be paid to all of our executive officers, including the named executive officers. Our Compensation Committee consists solely of independent members of the Board. In making its executive compensation determinations, the Compensation Committee considers recommendations from the Chief Executive Officer for executive officers other than himself and, with respect to the evaluation of the Chief Executive Officer’s performance, the Compensation Committee considers recommendations from the Chairman of the Board. In making his recommendations for executive officers other than himself, the Chief Executive Officer receives input from our human resources department and has access to various third party compensation surveys and compensation data

provided by the independent compensation consultant to the Compensation Committee, as described below. While the Chief Executive Officer discusses his recommendations for the other executive officers with the Compensation Committee, he does not participate in the deliberations concerning, or the determination of, his own compensation. In addition to our Chief Executive Officer, our Senior Vice President, Chief Human Resources Officer and Senior Vice President, General Counsel and Chief Compliance Officer may also attend Compensation Committee meetings from time to time and may take part in discussions of executive compensation. The Compensation Committee discusses and makes final determinations with respect to executive compensation matters without any named executive officers or other executive officers present (other than the Chief Executive Officer as described above). From time to time, various other members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in the Compensation Committee meetings.

The Compensation Committee meets periodically throughout the year to manage and evaluate our executive compensation program, and generally determines the principal components of compensation (base salary, performance bonus and equity awards) for our executive officers on an annual basis. These annual decisions typically occur in the first or second quarter of the year, however, decisions may occur during the year for new hires, promotions or other special circumstances as our Compensation Committee determines appropriate. The Compensation Committee does not delegate its authority to approve executive officer compensation. The Compensation Committee does not currently maintain a formal policy for the timing of equity awards to our executive officers and has granted awards over the past several years at times when the Compensation Committee determines appropriate.

Role of our Independent Compensation Consultant

The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive compensation, including the authority to approve the consultant’s reasonable fees and other retention terms. For purposes of evaluating 2017 compensation for each of our executive officers and making 2017 compensation decisions, we retained Compensia, an independent compensation consultant, to assist the Compensation Committee in reviewing our compensation programs and to ensure that our compensation programs remain competitive in attracting and retaining talented executives.

Compensia assisted the Compensation Committee in developing a group of peer companies to use as a reference in making 2017 compensation decisions, evaluating current pay practices and considering different compensation programs and best practices. As described further below, Compensia also prepared an analysis of our compensation practices with respect to base salaries, annual bonuses and long-term incentive grants against market practices. Compensia reported directly to the Compensation Committee, which maintained the authority to direct their work and engagement, and advised the Compensation Committee from time to time. Compensia interacted with management to gain access to Company information that is required to perform services and to understand the culture and policies of our organization. The Compensation Committee and Compensia met in executive session with no members of management present as needed to address various compensation matters, including deliberations regarding the Chief Executive Officer’s compensation.

Beginning in June 2017, the Compensation Committee retained Radford, an Aon Hewitt Company and a subsidiary of Aon plc, to assist the Compensation Committee in evaluating current pay practices, developing a pay philosophy, evaluating its peer group, evaluating compensation and corporate governance best practices and proxy advisory firm considerations and preparing to make 2018 compensation decisions.

Our Compensation Committee analyzed whether the work of Radford as a compensation consultant raised any conflict of interest, taking into consideration the following factors: (i) the fact that Radford and its affiliates do not provide any services directly to AveXis; (ii) the amount of fees paid to Radford and its affiliates by AveXis as a percentage of Radford and its affiliates’ total revenue; (iii) Radford’s policies and procedures that are designed to prevent conflicts of interest; (iv) any business or personal relationship of Radford or the individual compensation advisors employed by Radford with any executive officer; (v) any business or personal relationship of the individual compensation advisors with any member of our Compensation Committee; and (vi) any AveXis stock owned by Radford or the individual compensation advisors employed by Radford. Based on its analysis of these factors, our

Compensation Committee determined that the work of Radford and the individual compensation advisors employed by Radford does not create any conflict of interest.

Use of Competitive Market Compensation Data

We aim to attract and retain the most highly qualified executive officers in an extremely competitive market. Accordingly, the Compensation Committee believes that it is important when making its compensation decisions to be informed as to the current practices of comparable public companies with which we compete for top talent. To this end, the Compensation Committee reviews market data for each executive officer’s position, compiled by our compensation consultant, as described below, including information relating to the compensation for executive officers in the development stage biotechnology industry.

In developing a proposed list of our peer group companies to be used in connection with making compensation decisions for 2017, Compensia and the Compensation Committee selected companies that would be appropriate peers based on industry focus, employee size, stage of development and market capitalization. Specifically, companies were selected in the spring of 2017 with the following parameters: operating in the biotechnology and pharmaceuticals industries (with a preference for companies with a focus on genetics and/or rare disease or orphan drugs), which were pre-commercial with clinical stage operations, had employee headcounts of less than 200, and market capitalizations preferably from one-half ($900 million) to two times ($3.6 billion) AveXis’ market value at the time (with AveXis falling in the 55th percentile of such group of companies chosen). Based on these criteria, in March 2017, Compensia recommended, and our Compensation Committee approved, the following companies as our peer group for 2017:

Acceleron Pharma Inc.		Global Blood Therapeutics, Inc.
Aerie Pharmaceuticals, Inc.		Juno Therapeutics, Inc.
Agios Pharmaceuticals, Inc.		Kite Pharma, Inc.
Aimmune Therapeutics, Inc.		Puma Biotechnology, Inc.
Alder BioPharmaceuticals, Inc.		Sage Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.		Sarepta Therapeutics, Inc.
bluebird bio, Inc.		Spark Therapeutics, Inc.
Blueprint Medicines Corporation		Ultragenyx Pharmaceutical Inc.
Epizyme, Inc.		Xencor, Inc.
Five Prime Therapeutics, Inc.

In May 2017, Compensia completed an assessment of executive compensation data based on our peer group to inform the Compensation Committee’s determinations of executive compensation for 2017. This market data used for this assessment was compiled from (i) the 2017 selected peer group companies’ publicly disclosed information, or public peer data and (ii) data from the Radford Global Life Sciences Survey with respect to the 2017 selected peer group companies listed above, or the peer survey data. The components of the market data were based on the availability of sufficient comparative data for an executive officer’s position. The peer survey data and the public peer data are collectively referred to as market data, and was reviewed by the Compensation Committee, with the assistance of Compensia, and used as a reference point, in addition to other factors, in setting our named executive officers’ compensation.

Compensia prepared, and the Compensation Committee reviewed, a range of market data reference points (generally at the 25th, 50th, 60th and 75th percentiles of the market data) with respect to base salary, performance bonuses, equity compensation (value based on an approximation of grant date fair value), total target cash compensation (including both base salary and the annual target performance bonus) and total direct compensation (total target cash compensation and equity compensation).

The Compensation Committee’s general aim is for compensation to remain competitive with the market, falling above or below the median of the market data as appropriate based on corporate and individual executive performance, and other factors deemed to be appropriate by the Compensation Committee. Due to our limited history as a public company and our evolving and growing business, we have not developed a specific market positioning or “benchmark” that we consistently aim for in setting compensation levels; instead our Compensation Committee determines each element of compensation, and total target cash and direct compensation, for each named executive officer based on various facts and circumstances appropriate for our company in any given year. Competitive market positioning is only one of several factors, as described below under “Factors Used in Determining Executive Compensation,” that our Compensation Committee considers in making compensation decisions, and therefore individual named executive officer compensation may fall at varying levels as compared to the market data.

In preparation for making 2018 compensation decisions, with input from Radford, the Compensation Committee revalued its peer group and approved the following companies as our peers for 2018 executive compensation decisions:

ACADIA Pharmaceuticals Inc.		Juno Therapeutics, Inc.
Aerie Pharmaceuticals, Inc.		Kite Pharma, Inc.
Agios Pharmaceuticals, Inc.		Neurocrine Biosciences, Inc.
Aimmune Therapeutics, Inc.		Portola Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.		Puma Biotechnology, Inc.
bluebird bio, Inc.		Sage Therapeutics, Inc.
Blueprint Medicines Corporation		Sarepta Therapeutics, Inc.
Clovis Oncology, Inc.		Spark Therapeutics, Inc.
Global Blood Therapeutics, Inc.		Ultragenyx Pharmaceutical Inc.
Intercept Pharmaceuticals, Inc.

Factors Used in Determining Executive Compensation

Our Compensation Committee sets the compensation of our executive officers at levels they determine to be competitive and appropriate for each named executive officer, using their professional experience and judgment. Pay decisions are not made by use of a formulaic approach or benchmark; the Compensation Committee believes that executive pay decisions require consideration of a multitude of relevant factors that may vary from year to year and by individual circumstance. In making executive compensation decisions, the Compensation Committee generally takes into consideration the factors listed below.

· Corporate performance, business needs and business impact

· Each named executive officer’s individual performance, experience, job function, change in position or responsibilities, and expected future contributions to our company

· Internal pay equity among named executive officers and positions

· The need to attract new talent to our executive team and retain existing talent in a highly competitive industry

· A range of market data reference points (generally the 25th, 50th, 60th and 75th percentiles of the market data), as described above under “—Use of Competitive Market Compensation Data”

· The total compensation cost and stockholder dilution from executive compensation actions

· Trends and compensation paid to similarly situated officers within our market

· Recommendations of the outside compensation consultant

· A review of a named executive officer’s total targeted and historical compensation and equity ownership

· Our Chief Executive Officer’s recommendations (with respect to executive officers other than himself), based on his direct knowledge of the performance by each named executive officer

2017 Executive Compensation Program

Annual Base Salary

In reviewing and adjusting base salaries for 2017, the Compensation Committee considered current market data as well as each named executive officer’s total cash compensation (consisting of base salary and target bonus opportunity) and individual performance. The Compensation Committee made increases to the base salary of each of Mr. Nolan and Dr. Nagendran as necessary to bring each of their base salaries closer to the 50th percentile of the market data, to remain competitive with companies with whom we compete. Dr. L’Italien’s base salary did not trail the 50th percentile of the market data and as a result the Compensation Committee provided Dr. L’Italien with a smaller 3% merit increase which they felt was appropriate given the general cost of living increase in the market over the past year.

The named executive officers’ 2017 base salaries and increases from each of their 2016 base salaries, if applicable, are reflected in the table below. The 2017 base salaries were effective May 15, 2017, with the exception of Mr. Donenberg, whose base salary was effective upon his commencement with us as Chief Financial Officer on October 19, 2017. Mr. Donenberg’s base salary was set by the Compensation Committee at a level they felt appropriate to retain him, given his level of experience and historical compensation.

Named Executive Officer	2017 Base Salary		Increase from 2016 Base Salary
Sean P. Nolan	$	555,000	11	%
Phillip B. Donenberg (1)	$	350,000	(1	)
James J. L’Italien, Ph.D.	$	375,950	3	%
Raken B. Modi (2)	$	407,000	(2	)
Sukumar Nagendran, M.D.	$	426,000	8	%
Thomas J. Dee (3)	$	350,000	0	%

(1) Prior to his commencement as Chief Financial Officer, Mr. Donenberg served as our Vice President, Corporate Controller and his base salary in such role during 2017 was $284,625 (from April until October 2017) and $275,000 (from January through March 2017).

(2) Mr. Modi commenced as Senior Vice President, Chief Business Officer on February 13, 2017.

(3) Mr. Dee resigned as our Senior Vice President and Chief Financial Officer in October 2017.

Annual Performance-Based Bonuses

Our annual performance-based bonus program for 2017 was developed by our Compensation Committee in early 2017. Under the 2017 annual performance bonus program, each named executive officer was eligible to be considered for a performance bonus based on (1) the individual’s target bonus, as a percentage of base salary, (2) the percentage attainment of our 2017 corporate goals, or key success factors, established by the Compensation Committee, and, with respect to our named executive officers other than Mr. Nolan, (3) the percentage attainment of the 2017 individual goals established by the Compensation Committee, based on recommendations from Mr. Nolan, for each named executive officer.

The Compensation Committee determined that each executive officer other than Mr. Nolan’s performance bonus should be based in part on their own individual performance and contribution towards achievement of the key success

factors; accordingly, for each of the named executive officers other than Mr. Nolan, 80% of the bonus was based on key success factor achievement and 20% of the bonus was based on individual performance achievement. The Compensation Committee determined Mr. Nolan’s bonus should be based solely on the achievement of the key success factors, because as Chief Executive Officer, Mr. Nolan has greater impact on, and responsibility for, corporate performance. The Compensation Committee retained the discretion to make adjustments to the calculated bonus based on unexpected or unplanned events, the overall financial condition of the Company, extraordinary performance or underperformance or other factors as determined appropriate by the Compensation Committee, however, they capped the maximum total bonus pool available to be paid under the 2017 annual performance bonus program, upon maximum performance achievement, at 150% of total employee target bonuses.

Target Bonuses

In May 2017, the Compensation Committee reviewed the named executive officer target bonus percentages, and determined that the 2016 target bonus percentages remained appropriate for each of the named executive officers other than Mr. Nolan. Mr. Nolan’s target bonus percentage was increased from 50% to 60% and each of the other named executive officers’ 2017 target bonus percentage remained at 40%. The Compensation Committee determined Mr. Nolan’s increase in target bonus percentage was appropriate because his target bonus percentage, and total target cash compensation (consisting of base salary and target bonus) fell around the 25th percentile of the market data. The Compensation Committee’s increase in Mr. Nolan’s target bonus percentage, combined with his increase in base salary, was intended to set his total target cash compensation at approximately the 50th percentile of the market data, which the Compensation Committee felt was necessary to incentivize and retain Mr. Nolan. The Compensation Committee was mindful that the other named executive officers’ total target cash compensation generally aligned with the 50th percentile of the market data, and while Dr. L’Italien and Mr. Modi’s total target cash fell above the 50th percentile of the market data as a result of base salary level, the Compensation Committee determined that each of the officers should continue to have the same bonus percentage to reflect each of their similar degrees of impact on our organization and to promote internal equities amongst our senior leadership team.

Corporate Performance

The key success factors and relative overall weighting towards key success factor achievement for 2017 were established by the Compensation Committee in January 2017. Our Compensation Committee assigned a specific weighting to each of our key success factors on which the performance-based bonus for each executive officer would be based. In addition, the Compensation Committee set a total bonus pool payout range based on the overall level of achievement of the key success factors as reflected in the table below. Under this structure, overall key success factor achievement of less than 70% would result in zero bonus payment and if overall key success factor achievement was 130% or more, the total bonus pool would be capped at 150%.

	Level of Achievement of Key Success Factors		Bonus Pool Funding
Threshold	70	%	50	%
Target	100	%	100	%
Maximum	130	%	150	%

In early 2018, our Compensation Committee reviewed our performance and approved the extent to which we achieved each of our key success factors. The overall key success factor achievement was 135%, which was the sum of the weight of each key success factor, multiplied by the performance achievement assigned to such factor by the Compensation Committee based on the actual results during 2017. As a result, the total bonus pool was funded

at 150%.

Key Success Factor	Weight
Manage AVXS-101 good manufacturing practice, or GMP, product availability and manufacturing to support clinical trials and possible accelerated U.S. launch	35	%
Execute regulatory plans for SMA franchise	25	%
Execute clinical development and research plans for SMA franchise and new programs	20	%
Complete commercial readiness activities	15	%
Manage finances, execute business development plan, intellectual property development and human resources	5	%
Total	100	%

In February 2018, taking into account Mr. Nolan’s evaluation and recommendation, the Compensation Committee evaluated each of the named executive officers other than Mr. Nolan to determine the individual performance component of the performance bonus as follows:

· Mr. Donenberg: our Compensation Committee approved an individual performance factor payout for Mr. Donenberg (as reflected in the table below) based upon Mr. Donenberg’s exceptional work leading and building the accounting and finance functions/systems for AveXis as the Vice President and Controller and transitioning seamlessly to the SVP, Chief Financial Officer position.

· Dr. L’Italien: our Compensation Committee approved an individual performance factor payout for Dr. L’Italien (as reflected in the table below) of exceptional, based upon Dr. L’Italien’s significant contribution to value creation including orchestrating a successful CMC meeting with the FDA, successfully managing FDA information requests and conducting successful meetings with EMA, EU National Authorities and Japan.

· Mr. Modi: our Compensation Committee approved an individual performance factor payout for Mr. Modi (as reflected in the table below), based upon Mr. Modi’s expertise as the company’s senior commercial leader. He was foundational in leading the commercial readiness and preparatory activities to ensure a successful product launch.

· Dr. Nagendran: our Compensation Committee approved an individual performance factor payout for Dr. Nagendran (as reflected in the table below) of exceptional, based upon Dr. Nagendran’s leadership as the Chief Medical Officer coordinating all aspects of our clinical trials design and implementation, as well as being a liaison externally with patients, key opinion leaders and investors.

Based on our overall key success factor achievement and individual performance achievement (other than for Mr. Nolan) in February 2018, the Compensation Committee awarded each of our named executive officers the performance bonuses reflected in the table below.

Named Executive Officer	2017 Target Bonus		Total Payout
Sean P. Nolan	$	333,000	$	499,500
Phillip B. Donenberg (1)	$	112,959	$	163,790
James J. L’Italien, Ph.D.	$	150,380	$	238,051
Raken B. Modi (2)	$	162,800	$	232,920
Sukumar Nagendran	$	170,400	$	262,080
Thomas J. Dee (3)	$	140,000	$	0

(1) Mr. Donenberg’s bonus was pro-rated for the portion of 2017 in which Mr. Donenberg served as Chief Financial Officer.

(2) Mr. Modi’s bonus was paid for the full 2017 performance period pursuant to the terms of his employment agreement.

(3) Mr. Dee did not receive a performance bonus for 2017. However, as part of his severance payment, Mr. Dee received a pro-rated payment equal to his target performance bonus for 2017(based upon the portion of 2017 in which Mr. Dee was employed with us).

Equity-Based Incentive Awards

We have historically granted equity compensation to our executive officers primarily in the form of stock options, although from time to time we have granted other types of awards as the Compensation Committee determined appropriate. The Compensation Committee determined that our annual 2017 long-term compensation program for the named executive officers would continue to consist of stock options that vest over a four year period, subject to the executive’s continued service with us. The Compensation Committee considered the grant of other types of equity awards and concluded that for the 2017 annual equity award grants, stock options were the appropriate equity award type for our named executive officers, given our limited history as a public company, our executives’ familiarity with and understanding of stock options as incentive tools and the Compensation Committee’s belief that stock options serve as a key pay-for-performance tool in aligning the interests of our executive officers and our stockholders. The Compensation Committee views stock options as inherently performance-based compensation that automatically links executive pay to stockholder return, as the value realized, if any, by the executive from an award of stock options, is dependent upon, and directly proportionate to, appreciation in stock price. Regardless of reported value in the Summary Compensation Table, executives will only receive value from the stock option awards if the price of the stock increases above the price at time of grant, and remains above as the stock options continue to vest. Stock options also do not have downside protection, and the awards will not provide value to the holder when the stock price is below the exercise price. Additionally, the Compensation Committee reviewed market practices in May 2017 and was mindful that stock options are the predominant equity incentive vehicle used by our peer companies.

The Compensation Committee approved the following annual stock options for our named executive officers in May 2017 (except as otherwise noted below), each of which vest over a four-year period:

Named Executive Officer		Stock Option Grant (# shares)
Sean P. Nolan		96,000
Phillip B. Donenberg (1)		20,000
James J. L’Italien, Ph.D.		27,827
Raken B. Modi (2)		68,940
Sukumar Nagendran		25,200
Thomas J. Dee (3)		25,200

(1) Mr. Donenberg’s May 2017 grant reflected his annual equity grant in his role as Vice President, Corporate Controller and consisted of an option to purchase 5,594 shares. The Compensation Committee granted Mr. Donenberg an additional option to purchase 4,406 shares of our common stock in September 2017 and an additional option to purchase 10,000 shares of our common stock in October 2017, each of which vests over a four-year period. The Compensation Committee approved these additional grants because they felt these amounts were necessary to incentivize and retain Mr. Donenberg and commensurate with industry experience, exceptional performance and his increased position and duties as a result of his promotion to Senior Vice President, Chief Financial Officer.

(2) Mr. Modi’s May 2017 grant reflected his annual equity grant in his role as Senior Vice President, Chief Business Officer and consisted of an option to purchase 7,940 shares. The Compensation Committee also granted Mr. Modi an option to purchase 61,000 shares at the commencement of his employment to provide him for the value of equity he forfeited when leaving his former employer to join the Company.

(3) Mr. Dee’s stock options were forfeited as a result of his resignation as our Senior Vice President and Chief Financial Officer in October 2017.

The Compensation Committee chose each of the NEO’s grant level based on the amount which they felt, in their judgment, was appropriate to retain and incentivize the NEOs, while remaining reasonable within market standards and considering potential dilution of our share reserves. In making these determinations, the Compensation Committee considered each of the NEO’s current equity holdings, including vested and unvested holdings and the extent to which such holdings were “in-the-money,” the extent to which such holdings remained unvested and therefore continued to serve as a retention tool, the market data provided by Compensia reflecting equity value based on approximated grant date fair value, internal equity amongst the team, and individual performance.

Additionally, the Compensation Committee granted the following performance-vesting restricted stock units, or PRSUs, as a special retention and incentive award to certain executives in March 2017.

Named Executive Officer		PRSU Grant (# shares)
James J. L’Italien, Ph.D.		9,154
Sukumar Nagendran		9,906

The Compensation Committee felt these awards were necessary to retain Drs. L’Italien and Nagendran, who are critical to our key programs and structured the awards to vest only if specific performance milestones are achieved, thereby aligning the recipients’ interests with our success. These PRSU awards vest based upon two milestones; first, with respect to 50% of the shares upon U.S. FDA marketing authorization approval of AVXS-101 on or before the three year anniversary of the grant date, or the first milestone, and second, 50% of the shares upon

providing continuous supply of AVXS-101 to the market for 12 months following the first commercial sale that occurs within six months after the first milestone has occurred, or the second milestone, subject in both cases to continued service. The Compensation Committee determined the size of these awards based on their judgement regarding the amount necessary and reasonable to accomplish the desired incentive purposes of the awards.

Other Features of our Executive Compensation Program

Agreements with our Named Executive Officers

Employment Agreements

We have entered into employment agreements with each of our named executive officers that provide for the basic terms of their employment, including base salary, performance bonus opportunity and equity grants, as well as certain severance and change of control benefits. The terms of these agreements are described in greater detail in the section titled “Description of Compensation Arrangements.” Each of our named executive officers is employed at will and may be terminated at any time for any reason.

Severance and Change in Control Benefits

Regardless of the manner in which a named executive officer’s service terminates, the named executive officer is entitled to receive amounts earned during his or her term of service, including salary and unused vacation pay. Under our employment agreements, each of our named executive officers is eligible to receive severance benefits (including cash payments, payments for benefits continuation and equity acceleration) upon a termination without cause or resignation for good reason, either alone or within the three months prior to or 12 months following a change in control transaction. We do not provide any tax gross ups in connection with severance or change in control transactions, nor have we provided any “single trigger” severance cash payments upon a change in control without a termination event since our IPO. Some of our historical equity award granted to named executive officers prior to our IPO vest upon a change in control event, however all subsequent equity award agreements and the recent amended executive employment agreements provide for “double trigger” vesting provisions. Our Compensation Committee periodically reviews the severance and change in control benefits that we provide, including by reference to market data, to ensure that the benefits remain appropriately structured and at reasonable levels. The Compensation Committee most recently reviewed and made refinements to the severance and change in control benefits for our named executive officers in late 2016, which were memorialized in the amended and restated employment agreements executed in early 2018. The changes made included standardizing defined terms and benefits across the executive team and providing for enhanced severance payments and equity acceleration if a termination occurred in connection with a change in control. The Compensation Committee believes that severance protection benefits are necessary to provide stability among our executive officers, serve to focus our executive officers on our business operations, and avoid distractions in connection with a potential change in control transaction or period of uncertainty. A more detailed description of the severance plan and each of our named executive officer benefit levels thereunder is provided below under “Potential Payments upon Termination or Change in Control.”

In addition, each of our named executive officers holds equity awards under our equity incentive plans that were granted subject to our form of award agreements. A description of the termination and change in control provisions in such equity incentive plans and form of award agreements is provided below under “Equity Compensation Arrangements.”

Mr. Dee received severance benefits under the terms of a general release and waiver agreement we entered into with him in October 2017. In exchange for Mr. Dee’s release and waiver of claims in favor of our company, Mr. Dee received severance in the amount of twelve months of continued payment of base salary and a payment equal to his target performance bonus for 2017, pro-rated for the portion of the year in which he was employed with us in 2017.

Other Benefits

Our named executive officers are eligible to participate in all of our benefit plans, such as our Savings Investment Match Plan, or Simple IRA Plan (see the section below “Description of Compensation Arrangements—Retirement Benefits and Other Compensation”), medical, dental, vision, short-term disability, long-term disability, group life insurance, in each case generally on the same basis as other employees. We do not currently have qualified or nonqualified defined benefit plans or deferred compensation plans, nor do we offer pension or other retirement benefits other than our Simple IRA Plan, under which employees may contribute certain pre-tax compensation and we may make discretionary matching contributions, in each case subject to limitations under the Internal Revenue Code of 1986, as amended, or the Code. In 2017, we made matching contributions of 3% of each employee’s contribution, up to a maximum of 3% of such employee’s base salary.

We generally do not offer perquisites or personal benefits to our named executive officers, although we may from time to time provide reasonable relocation or signing bonuses or other benefits to our named executive officers as our Compensation Committee determines appropriate. Mr. Modi received a signing bonus of $181,200 in 2017 as an inducement to his commencement of employment with us and to make Mr. Modi whole for certain compensation he was foregoing at his previous employer. Mr. Modi was required to repay the bonus to us if he was terminated under certain circumstances or resigned within twelve months of his start date.

Accounting and Tax Considerations

Under Financial Accounting Standard Board ASC Topic 718, or ASC 718, the Company is required to estimate and record an expense for each award of equity compensation over the vesting period of the award. We record share-based compensation expense on an ongoing basis according to ASC 718. The accounting impact of our compensation programs are one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs.

Section 162(m) of the Code disallows a deduction to any publicly held corporation and its affiliates for certain compensation paid to “covered employees” in a taxable year to the extent that compensation to a covered employee exceeds $1 million. Prior to the recent enactment of the U.S. Tax Cuts and Jobs Act in December 2017, or the U.S. Tax Act, compensation that qualified as “performance-based compensation” under Section 162(m) of the Code was not subject to this deduction limitation. Pursuant to the U.S. Tax Act, this exception for “performance-based compensation” under Section 162(m) of the Code was repealed, with respect to taxable years beginning after December 31, 2017, except that certain transition relief is provided by the U.S. Tax Act for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date. As a result, compensation paid to any of our “covered employees” in excess of $1 million per taxable year generally will not be deductible unless among other requirements, it is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the transition relief provided by the U.S. Tax Act. Because of certain ambiguities and uncertainties as to the application and interpretation of Section 162(m) of the Code and the regulations issued thereunder, including the uncertain scope of the transition relief provided by the U.S. Tax Act, no assurance can be given that any compensation paid by the company will be eligible for such transition relief and, therefore, eligible for the “performance-based compensation” exception under Section 162(m) of the Code. The compensation committee will continue to monitor the applicability of Section 162(m) of the Code to its ongoing compensation arrangements.

Clawbacks

As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse our Company for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the Sarbanes-Oxley Act of 2002. Additionally, we intend to implement a Dodd-Frank Wall Street Reform and Consumer Protection Act-compliant clawback policy as soon as, and to the extent that, the requirements of such clawbacks are finalized by the SEC.

Risk Assessment Concerning Compensation Practices and Policies

With the assistance of the Compensation Committee’s compensation consultant and the Company’s outside counsel, in March 2018, the Compensation Committee reviewed the Company’s compensation policies and practices to assess whether they encourage employees to take inappropriate risks. After reviewing and assessing the Company’s compensation philosophy, terms and practices, including the mix of fixed and variable, short and long-term incentives and overall pay, incentive plan structures, and the checks and balances built into, and oversight of, each plan and practice, the Compensation Committee determined that any risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on our Company as a whole. The Compensation Committee believes that the mix and design of the elements of executive compensation do not encourage management to assume excessive risks; the mix of short-term compensation (in the form of salary and annual bonus, if any, which is based on a variety of performance factors), and long-term compensation (in the form of stock options) prevents undue focus on short-term results and helps align the interests of the Company’s executive officers with the interests of our stockholders. In addition, the Company’s insider trading policy and prohibition against hedging and pledging in Company stock protects against short-term decision making.

Conclusion

It is the opinion of the Compensation Committee that the compensation policies and elements described above provide the necessary incentives to properly align our executive officers’ performance with the interests of our stockholders while maintaining equitable and competitive executive compensation practices that enable us to attract and retain the highest caliber of executive officers.

Compensation Committee Interlocks and Insider Participation

None of the current members of our Compensation Committee has ever been an executive officer or employee of ours. None of our executive officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee.

Report of the Compensation Committee of the Board of Directors

The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis (“CD&A”) contained in this Form 10-K. Based on this review and discussion, the Compensation Committee has recommended to the Board of Directors that the CD&A be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Dr. Frank Verwiel, Chair
Mr. Terrance Kearney
Dr. Joao Siffert

The material in this report is not “soliciting material,” is not deemed “filed” with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Summary Compensation Table

The following table shows for the fiscal years ended 2017, 2016 and 2015, compensation awarded to or paid to, or earned by the named executive officers.

SUMMARY COMPENSATION TABLE

Name and Principal Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)(1)	Option Awards ($) (2)	Non-Equity Incentive Plan Compensation ($)		All Other Compensation ($)		Total ($)
Sean P. Nolan President and Chief Executive Officer	2017	533,000		—		—	5,447,229	499,500		2,500		6,482,229
	2016(16)	448,462		—		—	3,504,600	302,712		—		4,255,774
	2015	227,077	(3)	—		—	8,035,702	180,000	(4)	—		8,442,779
Phillip B. Donenberg Senior Vice President and Chief Financial Officer (15)	2017	295,129	(5)	—		—	1,411,725	163,790		11,244	(6)	1,881,888
	2016	—		—		—	—	—		—		—
	2015	—		—		—	—	—		—		—
James J. L’Italien Senior Vice President and Chief Regulatory and Quality Officer (15)	2017	371,570		—		730,032	1,578,959	238,051		2,500		2,921,112
	2016	—		—		—	—	—		—		—
	2015	—		—		—	—	—		—		—
Raken B. Modi Senior Vice President and Chief Business Officer (15)	2017	346,719	(7)	181,200	(8)	—	3,037,957	232,920		11,187	(6)	3,809,983
	2016	—		—		—	—	—		—		—
	2015	—		—		—	—	—		—		—
Sukumar Nagendran Senior Vice President and Chief Medical Officer	2017	413,600		—		790,004	1,429,898	262,080		14,757	(6)	2,910,339
	2016(16)	395,000		—		—	1,202,715	213,300		42,000	(9)	1,853,015
	2015	113,943	(10)	233,000	(11)	—	2,409,890	—		12,483	(9)	2,769,316
Thomas J. Dee Former Senior Vice President and Chief Financial Officer	2017	284,038	(12)	—		—	1,429,898	—		183,356	(13)	1,897,292
	2016(16)	350,000		—		—	1,202,715	189,000		—		1,741,715
	2015	141,346	(14)	—		—	2,148,222	88,000	(4)	—		2,377,568

(1) Represents the grant date fair market value of performance-based restricted stock units granted to Drs. L’Italien and Nagendran in March 2017 computed in accordance with ASC Topic 718, Compensation—Stock Compensation. These units have not vested as of December 31, 2017. The amounts reported are calculated based on the probable satisfaction of the performance conditions for such awards at the time of grant. For fiscal year 2017, the probable outcome on the date of grant was the target outcome and also equal to the value of the award assuming the highest level of performance conditions were achieved.

(2) The amounts reflect the full grant date fair value for awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. Unlike the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 10 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

(3) Mr. Nolan’s employment commenced with us on June 8, 2015. The 2015 salary reported reflects the pro rata portion of Mr. Nolan’s annual salary of $400,000 earned during 2015 from commencement of his employment through December 31, 2015.

(4) Messrs. Nolan and Dee were entitled to bonuses, pro-rated for days of service in 2015, calculated as a target percentage of their annual base salary based upon our Compensation Committee’s assessment of their performance and our Company’s attainment of targeted goals as set by the Compensation Committee in its sole discretion.

(5) Mr. Donenberg’s service as our Senior Vice President and Chief Financial Officer commenced on October 19, 2017. The 2017 salary reported reflects Mr. Donenberg’s salary as our Vice President, Corporate Controller earned through October 19, 2017 and the pro-rated portion of his annual salary of $350,000 for service as our Senior Vice President and Chief Financial Officer earned during 2017 from commencement of his service in that role through December 31, 2017.

(6) Reflects matching contributions to the Company’s Simple IRA Plan.

(7) Mr. Modi’s employment with us commenced on February 13, 2017. The 2017 salary reported reflects the pro rata portion of Mr. Modi’s annual salary of $385,000 earned during 2017 from commencement of his employment through December 31, 2017.

(8) Mr. Modi received a signing bonus of $181,200 in 2017 as an inducement to his commencement of employment with us and to provide him the value of compensation he was foregoing when leaving his former employer to join the Company. Mr. Modi was required to repay the bonus to us if he was terminated under certain circumstances or resigned within twelve months of his start date.

(9) Represents a monthly allowance of $3,500 to offset Dr. Nagendran’s cost of housing and ground transportation in connection with his relocation to Chicago.

(10) Dr. Nagendran’s employment commenced with us on September 14, 2015. The 2015 salary reported reflects the pro rata portion of Dr. Nagendran’s annual salary of $395,000 earned during 2015 from commencement of his employment through December 31, 2015.

(11) Represents a one-time cash signing bonus of $75,000 and a guaranteed bonus of 40% of his base salary earned pursuant to his employment agreement, which is described further under “—Employment Agreements—Dr. Nagendran.”

(12) Mr. Dee resigned as our Senior Vice President and Chief Financial Officer on October 9, 2017.

(13) Includes $180,856 paid to Mr. Dee as severance during 2017. See “—Employment Agreements—Mr. Dee” and “—Potential Payments Upon Termination or Change in Control at December 31, 2017.”

(14) Mr. Dee’s employment commenced with us on August 3, 2015. The 2015 salary reported reflects the pro rata portion of Mr. Dee’s annual salary of $350,000 earned during 2015 from commencement of his employment through December 31, 2015.

(15) Messrs. Donenberg and Modi and Dr. L’Italien were not named executive officers for the fiscal years ended 2015 and 2016.

(16) Amounts shown reflect corrections to previously reported amounts to such named executive officer’s non-equity incentive plan compensation for fiscal year 2016.

Grants of Plan-Based Awards

The following table shows for the fiscal year ended December 31, 2017, certain information regarding grants of plan-based awards to the named executive officers:

GRANTS OF PLAN-BASED AWARDS IN FISCAL 2017

	Award		Estimated Future Payouts Under Non-Equity Incentive Awards ($)(1)			Estimated Future Payouts Under Equity Incentive Plan Awards	All Other Option Awards: Number of Securities Underlying		Exercise or Base Price of Option Awards	Grant Date Fair Value of Stock and Option
Name	Type	Grant Date	Threshold	Target	Maximum	(#)(2)	Options (#)(3)		($/Sh)(4)	Awards ($)(5)
Sean P. Nolan	Option	May 10, 2017					96,000		77.24	5,447,229
	Cash	—		333,000
Phillip B. Donenberg	Option	May 10, 2017					5,594		77.24	317,415
	Option	September 15, 2017					4,406		88.08	308,009
	Option	October 19, 2017					10,000		100.52	786,301
	Cash	—		112,959
James J. L’Italien	Option	May 10, 2017					27,827		77.24	1,578,959
	PRSU	March 20, 2017				9,154				730,032
	Cash	—		150,380
Raken B. Modi	Option	May 10, 2017					7,940		77.24	450,531
	Option	February 13, 2017					61,000		57.88	2,587,425
	Cash	—		154,000
Sukumar Nagendran	Option	May 10, 2017					25,200		77.24	1,429,898
	PRSU	March 20, 2017				9,906				790,004
	Cash	—		170,400
Thomas J. Dee	Option	May 10, 2017					25,200	(6)	77.24	1,429,898
	Cash	—		157,200

(1) These columns sets forth the target bonus amounts for each named executive officer for the year ended December 31, 2017 under the annual performance-based bonus program. The dollar value of the actual bonus award earned for the year ended December 31, 2017 for each named executive officer is set forth in the Summary Compensation Table above. For a description of the performance-based bonus program, see “—Compensation Discussion and Analysis—2017 Executive Compensation Program—Annual Performance-Based Bonuses.”

(2) Awards designated “PRSU” reflect performance-based restricted stock unit awards under our 2016 Equity Incentive Plan. For additional information, see “—Compensation Discussion and Analysis—2017 Executive Compensation Program—Equity-Based Incentive Awards.” Amounts shown represent the target number of shares that may be earned under the PRSUs granted to such named executive officer in 2017 under the 2016 Plan. The PRSUs did not include threshold or maximum award amounts. The PRSUs vest upon the date based upon two milestones; first, with respect to 50% of the shares upon U.S. FDA marketing authorization approval of AVXS-101 on or before the three year anniversary of the grant date, or the first milestone, and as to 50% of the shares upon providing continuous supply of AVXS-101 to the market for 12 months following the first commercial sale that occurs within six months after the first milestone has occurred, or the second milestone, subject in both cases to continued service.

(3) Awards designated “Option” reflect awards of options to purchase shares of our common stock under our 2016 Equity Incentive Plan. For all option awards, 25% of the shares of common stock subject to the option grants vest on the first anniversary of the date of grant, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to the named executive officer’s service with us as of such date. For additional information, see “—Compensation Discussion and Analysis—2017 Executive Compensation Program—Equity-Based Incentive Awards.”

(4) Stock options were granted with an exercise price equal to 100% of the fair market value on the date of grant.

(5) For performance-based restricted stock unit awards, reflects the grant date fair value of performance-based restricted stock units based upon probable outcome of the performance conditions. For option awards, reflects the full grant date fair value for awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. The assumptions we used in valuing options are described in Note 10 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

(6) All of Mr. Dee’s unvested option awards were forfeited in connection with his separation from the Company in October 2017.

Narrative to Summary Compensation Table

The three principal components of our executive compensation program for our named executive officers in 2017 were base salary, annual performance-based bonuses and long-term incentive equity compensation. In line with our pay for performance philosophy, we structured a significant portion of our named executive officers’ 2017 compensation to be variable, at risk and tied directly to our measurable performance in the form of performance-based bonuses and long-term equity awards, as further described above under “Compensation Discussion and Analysis — Executive Summary.”

Description of Compensation Arrangements

Employment Agreements

We have entered into employment agreements with our named executive officers. The key terms of the agreements are described below, including a discussion of the severance pay and other benefits provided in connection with a termination of employment of these individuals.

Mr. Nolan

We entered into an employment agreement with Mr. Nolan, our Chief Executive Officer, in June 2015, which we later amended in February 2018. Pursuant to the terms of his employment agreement, Mr. Nolan’s employment is at will and may be terminated at any time by us or Mr. Nolan. Under the terms of the agreement, Mr. Nolan was originally entitled to receive an annual base salary of $400,000, later increased by the compensation committee of our board of directors, or the Compensation Committee, to $555,000 in 2017 and $605,000 in 2018, and an annual target bonus of 45%, later increased by the Compensation Committee to 60%, of his annual base salary, based upon the assessment by the Compensation Committee, of Mr. Nolan’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. Pursuant to his agreement, Mr. Nolan also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

Mr. Donenberg

We entered into an employment agreement with Mr. Donenberg, our Senior Vice President and Chief Financial Officer, in October 2017. Pursuant to the terms of his employment agreement, Mr. Donenberg’s employment is at will and may be terminated at any time by us or Mr. Donenberg. Under the terms of the agreement, Mr. Donenberg is entitled to receive an annual base salary of $350,000, increased by the Compensation Committee to $385,000 in 2018,and an annual target bonus of 40% of his annual base salary based upon the Compensation Committee’s assessment of Mr. Donenberg’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. In accordance with the agreement, Mr. Donenberg was also granted an option to purchase 10,000 shares of our common stock. 25% of the shares subject to the option will vest on October 19, 2018

(the first anniversary of the Effective Date) and the remaining shares vest in 36 equal monthly installments thereafter, subject to Mr. Donenberg’s continued service. Pursuant to his agreement, Mr. Donenberg also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

Dr. L’Italien

We entered into an employment agreement with Dr. L’Italien, our Senior Vice President and Chief Regulatory and Quality Officer, in June 2015, which we later amended in February 2018. Pursuant to the terms of his employment agreement, Dr. L’Italien’s employment is at will and may be terminated at any time by us or Dr. L’Italien. Under the terms of the agreement, Dr. L’Italien is entitled to receive an annual base salary of $365,000, later increased by the Compensation Committee to $375,950 in 2018, and an annual target bonus of 40% of his annual base salary, based upon the assessment by the Compensation Committee of Dr. L’Italien’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. Pursuant to his agreement, Dr. L’Italien also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

Mr. Modi

We entered into an employment agreement with Mr. Modi, our Senior Vice President and Chief Business Officer, in January 2017. Pursuant to the terms of his employment agreement, Mr. Modi’s employment is at will and may be terminated at any time by us or Mr. Modi. Under the terms of the agreement, Mr. Modi is entitled to receive an annual base salary of $385,000, later increased by the Compensation Committee to $419,000 in 2018, and an annual target bonus of 40% of his annual base salary, based upon the assessment by the Compensation Committee of Mr. Modi’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. Mr. Modi was also entitled to a one-time sign-on bonus paid in 2017, in the aggregate amount of $181,200, consisting of a payment of $18,750 and $162,450 as an inducement to his commencement of employment with us and to make Mr. Modi whole for certain compensation he was foregoing at his previous employer, respectively. Mr. Modi was required to repay the bonus to us if he was terminated under certain circumstances or resigned within twelve months of his start date. Pursuant to his agreement, Mr. Modi also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

Dr. Nagendran

We entered into an employment agreement with Dr. Nagendran, our Senior Vice President and Chief Medical Officer, in August 2015, which we later amended in February 2018. Pursuant to the terms of his employment agreement, Dr. Nagendran’s employment is at will and may be terminated at any time by us or Dr. Nagendran. Under the terms of the agreement, Dr. Nagendran is entitled to receive an annual base salary of $395,000, later increased by the Compensation Committee to $426,000, and an annual target bonus of 40% of his annual base salary, based upon the assessment by the Compensation Committee of Dr. Nagendran’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. Dr. Nagendran was entitled to a one-time sign-on bonus of $75,000. Additionally, Dr. Nagendran received a monthly relocation allowance of $3,500 through December 31, 2016. Pursuant to his agreement, Dr. Nagendran also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

Mr. Dee

We entered into an employment agreement with Mr. Dee, our former Senior Vice President and Chief Financial Officer, in July 2015. Pursuant to the terms of his employment agreement, Mr. Dee’s employment was at will and could be terminated at any time by us or Mr. Dee. Under the terms of the agreement, Mr. Dee was entitled to receive an annual base salary of $350,000 and an annual target bonus of 40% of his annual base salary based upon the Compensation Committee’s assessment of Mr. Dee’s performance and our attainment of targeted goals as set by the Compensation Committee in its sole discretion. Pursuant to his agreement, Mr. Dee also entered into an employee proprietary information, inventions assignment, non-solicitation and non-competition agreement with us.

In October 2017, we entered into a severance agreement with Mr. Dee. Pursuant to the severance agreement, we will pay Mr. Dee $350,000, his annual base salary, through October 2018, the first anniversary of his resignation

date, as well as all accrued and unused vacation earned through his resignation date. We also paid Mr. Dee’s pro rata bonus for 2017 of $108,164, representing the target bonus amount of 40% of his annual base salary.

Equity Compensation Arrangements

Prior to the closing of our initial public offering, we granted all equity awards pursuant to our Amended and Restated 2014 Stock Plan (the “2014 Plan”) and following the closing of our initial public offering, we grant all equity awards pursuant to our 2016 Equity Incentive Plan (“2016 Plan”).

2016 Equity Incentive Plan

Our board of directors adopted our 2016 Plan in January 2016, and our stockholders approved our 2016 Plan in February 2016. On and after the date of our initial public offering, no additional stock awards will be granted under the 2014 Plan.

Administration. Our Board of Directors, or a duly authorized committee thereof, has the authority to administer the 2016 Plan. Our Board of Directors may also delegate to one or more of our officers the authority to (1) designate employees (other than other officers) to be recipients of certain stock awards, and (2) determine the number of shares of common stock to be subject to such stock awards. Subject to the terms of the 2016 Plan, our Board of Directors or the authorized committee thereof, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award.

Types of Awards. The 2016 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation, or collectively, stock awards. Additionally, the 2016 Plan provides for the grant of performance cash awards. Incentive stock options may be granted only to employees. All other awards may be granted to employees, including officers, non-employee directors, and consultants.

Corporate Transactions. In the event of certain specified significant corporate transactions (or a change in control, as described below), the plan administrator may take any one or more of the following actions as to outstanding awards, or as to a portion of any outstanding award under the 2016 Plan:

· arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company;

· arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company;

· accelerate the vesting of the stock award and provide for its termination prior to the effective time of the transaction;

· arrange for the lapse of any reacquisition or repurchase rights held by us with respect to the stock award;

· cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as our plan administrator may deem appropriate; and

· make a payment equal to the excess, if any, of the value of the property the participant would have received upon exercise of the stock award immediately prior to the effective time of the transaction over any exercise price otherwise payable by the participant in connection with such exercise.

Change in Control. In addition to the above, the plan administrator may provide, in an individual award agreement, that the stock award will be subject to additional acceleration of vesting and exercisability in the event of

a certain specified change in control. However, in the absence of such a provision, no such acceleration of the stock award will occur.

Amended and Restated 2014 Stock Plan

Our Board of Directors adopted and our stockholders initially approved the 2014 Plan in January 2014 and amended and restated the 2014 Plan in August 2014.

Types of Awards. The 2014 Plan provided for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. ISOs could be granted only to employees. All other awards could be granted to directors, officers and employees of the Company.

Change in Control. In the event of certain change in control transactions affecting us (as described below), all stock options that are not exercisable will become immediately exercisable in full and the restriction period applicable to any outstanding restricted stock will lapse and the performance period applicable to any outstanding performance share shall lapse and, each share of common stock available under the 2014 Plan (whether or not subject to an outstanding award) will be converted pursuant to the change in control transaction

For purposes of the treatment above, a “change in control” generally means either of the following transactions, where the holders of our common stock receive shares of common stock registered under Section 12 of the Exchange Act in the transaction:

· a reorganization, merger, consolidation or sale of substantially all of our assets in a transaction in which our stockholders immediately prior to the transaction do not own at least 50% of the voting power of the surviving, resulting or transferee entity, except if our incumbent board will constitute at least a majority of the board or managers of the resulting entity (if our common stock is registered under Section 12 of the Exchange Act); or

· the consummation of a plan of our complete liquidation or dissolution.

In the event of certain other change in control transactions affecting us (as described below), each outstanding award under the 2014 Plan shall be surrendered to us and immediately cancelled and the holder will receive a cash payment from us in an amount generally equal to the number of shares underlying the award, multiplied by the greater of (i) the highest per share price offered to the Company stockholders in any transaction whereby the change in control takes place or (ii) the fair market value of a share of our common stock on the date of the change in control, in any case reduced by any purchase price per share for the award, as applicable. Performance-based awards will be deemed to be satisfied at the maximum level.

A “change in control” for purposes of this treatment generally means the transactions described above, but where the holders of our common stock receive consideration in the transaction other than shares of common stock registered under Section 12 of the Exchange Act, and in addition, the following transactions

· the acquisition by a person or group of beneficial ownership of 50% or more of the outstanding stock or combined voting power of securities entitled to vote; or

· if our common stock is registered under Section 12 of the Exchange Act, a change in the composition of our board of directors over a two year period that results in a majority of current directors (or successor directors approved by our current directors) not being continuing directors.

The definition of “change in control” under the 2014 Plan in any case excludes purchases or sales of stock by or from us or one of our employee benefit plans or trusts.

Retirement Benefits and Other Compensation

Our named executive officers did not participate in, or otherwise receive any benefits under, any pension, retirement or deferred compensation plan sponsored by us during 2015, 2016 and 2017. Our named executive officers were eligible to participate in our employee benefits, including medical, dental, vision, short-term disability, long-term disability, group life insurance and our employee Simple IRA Plan and our employer matching program, on the same basis as our other employees. In January 2018, we established a 401(k) plan, which our named executive officers are eligible to participate in on the same basis as our other employees. We generally do not provide perquisites or personal benefits except in limited circumstances, and we did not provide any perquisites or personal benefits to our named executive officers in 2015, 2016 or 2017, except that, pursuant to his employment agreement, through December 31, 2016, we paid Dr. Nagendran a monthly relocation allowance of $3,500, totaling $12,483 in 2015 and $42,000 in 2016, to offset the cost of his housing and ground transportation in connection with his relocation to Chicago. See “—Employment Agreements—Dr. Nagendran.” We matched contributions to our Simple IRA Plan for participating employees.

Potential Payments upon Termination or Change in Control

Mr. Nolan

Pursuant to his original employment agreement, Mr. Nolan was entitled to severance benefits if his employment was terminated without cause or if he resigned for good reason, subject to his execution of a release. If Mr. Nolan was terminated without cause or resigned for good reason, he was eligible to receive 12 months of continued base salary and premiums for continued health coverage or, if such termination or resignation occurred within the 12 months following a sale event, as defined in Mr. Nolan’s original employment agreement, 18 months.

Pursuant to his amended employment agreement, effective February 2018, if Mr. Nolan is terminated without cause or resigns for good reason, he is eligible to receive 12 months of continued base salary and premiums for continued health coverage, or, if such termination or resignation occurs within the three months prior to or 12 months following a change in control, as defined in Mr. Nolan’s employment agreement, 18 months of continued base salary, a bonus severance payment equal to the sum of Mr. Nolan’s (i) target annual performance bonus for the year in which the change in control occurs, divided by the total number of days in such performance year, plus (ii) Mr. Nolan’s target annual performance bonus for the year in which the change in control occurs, multiplied by 150%, premiums for continued health coverage and accelerated vesting in full of any outstanding stock awards granted during Mr. Nolan’s employment term. Such benefits are subject to his execution of a release.

Mr. Donenberg

Pursuant to his employment agreement, if Mr. Donenberg is terminated without cause or resigns for good reason, he is eligible to receive 12 months of continued base salary and premiums for continued health coverage, or, if such termination or resignation occurs within the three months prior to or 12 months following a change in control, as defined in Mr. Donenberg’s employment agreement, 12 months of continued base salary, a bonus severance payment equal to the prorated amount of his target annual performance bonus for the year in which the change of control occurs, premiums for continued health coverage and accelerated vesting in full of any outstanding stock awards granted during Mr. Donenberg’s employment term. Such benefits are subject to his execution of a release.

Dr. L’Italien

Pursuant to his original employment agreement, Dr. L’Italien was entitled to severance benefits if his employment was terminated without cause or if he resigned for good reason, subject to his execution of a release. If Dr. L’Italien was terminated without cause or resigned for good reason, he was eligible to receive 12 months of continued base salary and premiums for continued health coverage or, if such termination or resignation occurred within the 12 months following a sale event, as defined in Dr. L’Italien’s original employment agreement, 18 months of continued base salary and premiums for continued health coverage.

Pursuant to his amended employment agreement, effective February 2018, if Dr. L’Italien is terminated without cause or resigns for good reason, he is eligible to receive 12 months of continued base salary and premiums for continued health coverage, or, if such termination or resignation occurs within the three months prior to or

12 months following a change in control, as defined in Dr. L’Italien’s employment agreement, 18 months of continued base salary, a bonus severance payment equal to the prorated amount of his target annual performance bonus for the year in which the change of control occurs, premiums for continued health coverage and accelerated vesting in full of any outstanding stock awards granted during Dr. L’Italien’s employment term. Such benefits are subject to his execution of a release.

Mr. Modi

Pursuant to his employment agreement, if Mr. Modi is terminated without cause or resigns for good reason, he is eligible to receive 12 months of continued base salary and premiums for continued health coverage, or, if such termination or resignation occurs within the three months prior to or 12 months following a change in control, as defined in Mr. Modi’s employment agreement, 12 months of continued base salary, a bonus severance payment equal to the prorated amount of his target annual performance bonus for the year in which the change of control occurs, premiums for continued health coverage and accelerated vesting in full of any outstanding stock awards granted during Mr. Modi’s employment term. Such benefits are subject to his execution of a release.

Dr. Nagendran

Pursuant to his original employment agreement, Dr. Nagendran was entitled to severance benefits if his employment was terminated without cause or if he resigned for good reason, subject to his execution of a release. If Dr. Nagendran was terminated without cause or resigned for good reason, he was eligible to receive 12 months of continued base salary and premiums for continued health coverage or, if such termination or resignation occurred within the 12 months following a sale event, as defined in Dr. Nagendran’s original employment agreement, 18 months of continued base salary and premiums for continued health coverage.

Pursuant to his amended employment agreement, effective February 2018, if Dr. Nagendran is terminated without cause or resigns for good reason, he is eligible to receive 12 months of continued base salary and premiums for continued health coverage, or, if such termination or resignation occurs within the three months prior to or 12 months following a change in control, as defined in Dr. Nagendran’s employment agreement, 18 months of continued base salary, a bonus severance payment equal to the prorated amount of his target annual performance bonus for the year in which the change of control occurs, premiums for continued health coverage and accelerated vesting in full of any outstanding stock awards granted during Dr. Nagendran’s employment term. Such benefits are subject to his execution of a release.

Mr. Dee

Pursuant to his employment agreement, Mr. Dee was entitled to severance benefits if his employment was terminated without cause or if he resigned for good reason, subject to his execution of a release. If Mr. Dee was terminated without cause or resigned for good reason, he was eligible to receive 12 months of continued base salary and premiums for continued health coverage or, if such termination or resignation occurred within the 12 months following a sale event, as defined in Mr. Dee’s employment agreement, 18 months of continued base salary and premiums for continued health coverage.

As described above in “—Description of Compensation Arrangements—Employment Agreements—Mr. Dee,” in connection with his resignation from the Company we entered into a severance agreement with Mr. Dee in October 2017, pursuant to which we are paying certain severance benefits.

Outstanding Equity Awards at December 31, 2017

The following table shows certain information regarding outstanding equity awards at December 31, 2017 for the named executive officers. For all option awards, 25% of the shares of common stock subject to the option grants vest on the first anniversary of the date of grant, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, subject to the named executive officer’s service with us as of such date. Performance-based restricted stock units vest upon the achievement of certain regulatory and manufacturing milestones, as described below.

OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2017

		Option Awards				Stock Awards
Name	Grant Date	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)		Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)
Sean P. Nolan	May 10, 2017	0	96,000	77.24	May 10, 2027	—		—	—
	June 20, 2016	41,250	68,750	42.61	June 20, 2026	—		—	—
	June 10, 2015	461,438	276,862	15.94	June 10, 2025	—		—	—
Phillip B. Donenberg	October 19, 2017	—	10,000	100.52	October 19, 2027	—		—	—
	September 15, 2017	—	4,406	88.08	September 15, 2027	—		—	—
	May 10, 2017	—	5,594	77.24	May 10, 2027	—		—	—
	September 6, 2016	6,250	13,750	37.58	September 6, 2026	—		—	—
James J. L’Italien	May 10, 2017	—	27,827	77.24	May 10, 2027	—		—	—
	June 20, 2016	14,156	23,594	42.61	June 20, 2026	—		—	—
	August 11, 2015	96,397	60,087	18.17	August 11, 2025	—		—	—
	March 20, 2017	—	—	—	March 20, 2020	9,154	(1)	1,013,073	730,032
Raken B. Modi	May 10, 2017	—	7,940	77.24	May 10, 2027	—		—	—
	February 13, 2017		61,000	57.88	February 13, 2027	—		—	—
Sukumar Nagendran	May 10, 2017	—	25,200	77.24	May 10, 2027	—		—	—
	June 20, 2016	14,156	23,594	42.61	June 20, 2026	—		—	—
	August 11, 2015	91,713	87,437	18.17	August 11, 2025	—		—	—
	March 20, 2017	—	—	—	March 20, 2020	9,906	(1)	1,096,297	790,004
Thomas J. Dee	—	—	—	—	—	—		—	—

(1) Represents PRSUs, which vest upon the date based upon two milestones; first, with respect to 50% of the shares upon U.S. FDA marketing authorization approval of AVXS-101 on or before the three year anniversary of the grant date, or the first milestone, and as to 50% of the shares upon providing continuous supply of AVXS-101 to the market for 12 months following the first commercial sale that occurs within six months after the first milestone has occurred, or the second milestone, subject in both cases to continued service.

Option Exercises and Stock Vested

The following table shows for the fiscal year ended December 31, 2017, certain information regarding option exercises and stock vested during the last fiscal year with respect to the named executive officers:

OPTION EXERCISES AND STOCK VESTED IN FISCAL 2017

	Option Awards
Name	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise ($)
Sean P. Nolan	—	—
Phillip B. Donenberg	—	—
James J. L’Italien	—	—
Raken B. Modi	—	—
Sukumar Nagendran	16,021	1,107,317
Thomas J. Dee	100,662	6,794,972

Potential Payments Upon Termination or Change in Control at December 31, 2017

The following table estimates the potential severance payments and benefits to which the named executive officers would be entitled in connection with specified termination events under such named executive officer’s employment agreement, calculated as if each named executive officer’s employment had terminated as of December 31, 2017. There are no other agreements, arrangements or plans that entitle any named executive officers to severance, perquisites or other benefits upon termination of employment or a change in control.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL AT DECEMBER 31, 2017

	Involuntary Termination (1)		Involuntary Termination in Connection with Change in Control (2)
Sean P. Nolan
Bonus severance payment	$	—	$	832,500
Continued base salary	555,000		832,500
Stock based compensation (3)	—		34,115,542
Premium for continued health coverage	23,349		34,874
Benefit Total	$	578,249	$	35,815,416

Phillip B. Donenberg
Bonus severance payment	$	—	$	140,000
Continued base salary	350,000		350,000
Stock based compensation (3)	—		1,393,026
Premium for continued health coverage	15,792		15,792
Benefit Total	$	365,792	$	1,898,818

James J. L’Italien
Bonus severance payment	$	—	$	150,380
Continued base salary	375,950		563,925
Stock based compensation (3)	—		9,107,185
Premium for continued health coverage	15,792		23,687
Benefit Total	$	391,742	$	9,845,177

Raken B. Modi
Bonus severance payment	$	—	$	154,000
Continued base salary	385,000		385,000
Stock based compensation (3)	—		3,485,624
Premium for continued health coverage	15,792		15,792
Benefit Total	$	400,792	$	4,040,416

Sukumar Nagendran
Bonus severance payment	$	—	$	170,400
Continued base salary	426,000		639,000
Stock based compensation (3)	—		11,632,463
Premium for continued health coverage	23,249		34,874
Benefit Total	$	449,249	$	12,476,737

(1) Termination without cause or resignation for good reason.

(2) Termination without cause or resignation for good reason within three months prior to, or twelve months following, a change in control.

(3) Reflects the aggregate value of (i) unvested stock options which will accelerate and vest and (ii) for Mr. L’Italien and Dr. Nagendran, unvested PRSUs which will vest at target, in each case calculated using a closing price of $110.67 per share on December 29, 2017, the last trading day of 2017

The following table shows amounts that we have agreed to pay to Mr. Dee in connection with his resignation from the Company on October 9, 2017:

Bonus severance payment	$	108,164
Continued base salary	350,000
Benefit Total	$	458,164

Non-Employee Director Compensation

Our Board of Directors approved a compensation program for our non-employee directors that became effective in February 2016. For fiscal year 2017, this program provided for the following compensation to our non-employee directors:

· The non-executive chair of our Board of Directors will receive an annual fee from us of $70,000 and each other non-employee director will receive $40,000;

· The chair of our Audit Committee will receive an annual fee from us of $18,000 and each other member will receive $8,000;

· The chair of our Compensation Committee will receive an annual fee from us of $15,000 and each other member will receive $6,000;

· The chair of our Nominating and Corporate Governance Committee will receive an annual fee from us of $10,000 and each other member will receive $4,500; and

· Each non-employee director will be entitled to an initial option grant to purchase our common stock with an aggregate Black-Scholes option value of $270,000, or, with respect to our chairman, $405,000, and an annual option grant to purchase our common stock with an aggregate Black-Scholes option value of $125,000 under our 2016 Equity Incentive Plan.

In March 2018, our Board of Directors approved the following changes to the program:

· The chair of our Audit Committee will receive an annual fee from us of $20,000 and each other member will receive $10,000;

· Each member of our Compensation Committee will receive an annual fee from us of $7,500;

· Each member of our Nominating and Corporate Governance Committee will receive an annual fee from us of $5,000; and

· Each non-employee director will be entitled to an initial option grant to purchase our common stock with an aggregate Black-Scholes option value of $750,000, and an annual option grant to purchase our common stock with an aggregate Black-Scholes option value of $375,000 under our 2016 Equity Incentive Plan.

All fees under the director compensation policy are paid in equal quarterly installments and no per meeting fees are paid. We also reimburse non-employee directors for reasonable expenses incurred in connection with attending board of director and committee meetings.

Directors who are also our employees receive no additional compensation for their services as directors and are not set forth in the table below.

Director Compensation Table

The following table shows for the fiscal year ended December 31, 2017, certain information with respect to the compensation of all non-employee directors of the Company:

DIRECTOR COMPENSATION FOR FISCAL YEAR 2017

Name	Fees Earned or Paid in Cash ($)	Option Awards ($) (1)		Total ($)
Daniel Welch	78,904	125,002	(2)	203,906
Terrence Kearney	64,000	125,002	(3)	189,002
Bong Koh	44,500	125,002	(3)	169,502
Frank Verwiel	63,000	125,002	(3)	188,002
Paul Manning	48,000	125,002	(3)	173,002
Joao Siffert	29,690	395,025	(4)	424,715
Carole Nuechterlein (5)	33,435	—		33,435
Jonathan Leff (5)	33,104	—		33,104

(1) The amounts reflect the full grant date fair value for awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. Unlike the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 10 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

(2) Mr. Welch held 38,006 shares of common stock underlying outstanding option grants at December 31, 2017.

(3) Each of Drs. Koh and Verwiel, and Messrs. Kearney and Manning held 28,950 shares of common stock underlying outstanding option grants at December 31, 2017.

(4) Dr. Siffert held 7,755 shares of common stock underlying outstanding option grants at December 31, 2017.

(5) Ms. Nuechterlein and Mr. Leff chose not to stand for re-election to our Board of Directors at our 2017 annual meeting of stockholders, and accordingly, their service as directors terminated effective May 30, 2017. Neither Ms. Nuechterlein nor Mr. Leff held any shares of common stock underlying outstanding option grants at December 31, 2017.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Stock Ownership

The following table sets forth certain information regarding the ownership of the Company’s common stock as of March 15, 2018 by: (i) each director and nominee for director; (ii) each of the executive officers named in the Summary Compensation Table; (iii) all executive officers and directors of the Company as a group; and (iv) all those known by the Company to be beneficial owners of more than five percent of its common stock.

NAME AND ADDRESS OF BENEFICIAL OWNER	NUMBER OF SHARES OF COMMON STOCK BENEFICIALLY OWNED	PERCENTAGE OF SHARES OF COMMON STOCK BENEFICIALLY OWNED
Greater than 5% stockholders
FMR, LLC (1)	4,796,462	13.0	%
BlackRock, Inc. (2)	2,442,010	6.6	%
Vanguard Group (3)	1,867,092	5.1	%

Directors and Named Executive Officers
Sean P. Nolan (4)	612,761	1.6	%
Phillip B. Donenberg (5)	9,732	*
James J. L’Italien (6)	128,622	*
Raken B. Modi (7)	21,048	*
Sukumar Nagendran (8)	156,839	*
Daniel Welch (9)	31,010	*
Terrence C. Kearney (10)	24,218	*
Bong Koh (11)	1,059,875	2.9	%
Paul B. Manning (12)	1,718,949	4.6	%
Joao Siffert (13)	2,250	*
Frank Verwiel (10)	24,218	*
Thomas J. Dee	20,000	*
All current executive officers and directors as a group (18 persons)	5,773,669	15.1	%

* Represents beneficial ownership of less than one percent

(1) Information is based on a Schedule 13G/A filed with the SEC on February 13, 2018. The address of FMR, LLC is 245 Summer Street, Boston, Massachusetts 02210.

(2) Information is based on a Schedule 13G filed with the SEC on January 29, 2018. The address of BlackRock, Inc. is 55 East 52nd Street, New York, New York 10055.

(3) Information is based on a Schedule 13G filed with the SEC on February 8, 2018. The address of The Vanguard Group is 100 Vanguard Blvd., Malvern, Pennsylvania 19355.

(4) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 728,300 shares of common stock granted on June 10, 2015, which vested and became exercisable as to 25% of the shares on June 20, 2016, and then in 36 equal monthly installments thereafter, (ii) 110,000 shares of common stock granted on June 20, 2016, which vested and became exercisable as to 25% of the shares on June 20, 2017, and then in 36 equal monthly installments thereafter, and (iii) 96,000 shares of common stock granted on May 10, 2017, which will vest and become exercisable as to 25% of the shares on May 10, 2018, and then in 36 equal monthly installments thereafter.

(5) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to an option to purchase (i) 20,000 shares of common stock granted on September 5, 2016, which vested and became exercisable as to 25% of the shares on September 5, 2017, and then in 36 equal monthly installments thereafter, and (ii) 5,994 shares of common stock granted on May 10, 2017,

which will vest and become exercisable as to 25% of the shares on May 10, 2018, and then in 36 equal monthly installments thereafter.

(6) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 151,800 shares of common stock granted on August 11, 2015, which vests and becomes exercisable as to 25% of the shares on August 11, 2016, and then in 36 equal monthly installments thereafter, (ii) 37,750 shares of common stock granted on June 20, 2016, which vested and became exercisable as to 25% of the shares on June 20, 2017, and then in 36 equal monthly installments thereafter, and (iii) 27,827 shares of common stock granted on May 10, 2017, which will vest and become exercisable as to 25% of the shares on May 10, 2018, and then in 36 equal monthly installments thereafter.

(7) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to an option to purchase 61,000 shares of common stock granted on February 13, 2017, which vested and became exercisable as to 25% of the shares on February 13, 2018, and then in 36 equal monthly installments thereafter.

(8) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 199,855 shares of common stock granted on October 13, 2015, which vests and becomes exercisable as to 25% of the shares on September 14, 2016, and then in 36 equal monthly installments thereafter, (ii) 37,750 shares of common stock granted on June 20, 2016, which vested and became exercisable as to 25% of the shares on June 20, 2017, and then in 36 equal monthly installments thereafter, and (iii) 25,200 shares of common stock granted on May 10, 2017, which will vest and become exercisable as to 25% of the shares on May 10, 2018, and then in 36 equal monthly installments thereafter.

(9) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 35,552 shares of common stock granted on February 10, 2016, 8,385 of which vest and become exercisable in 12 equal monthly installments beginning on March 10, 2016, and 27,167 of which vest and become exercisable with respect to one-third of the shares on February 10, 2017, and then in 24 equal monthly installments thereafter, and (ii) 2,454 shares of common stock granted on May 30, 2017, which shall vest and become exercisable (x) in twelve equal monthly installments beginning on June 30, 2017, or (y) on the date of our Annual Meeting, whichever comes first.

(10) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 26,496 shares of common stock granted on February 10, 2016, 8,385 of which vest and become exercisable in 12 equal monthly installments beginning on March 10, 2016, and 18,111 of which vest and become exercisable with respect to one-third of the shares on February 10, 2017, and then in 24 equal monthly installments thereafter, and (ii) 2,454 shares of common stock granted on May 30, 2017, which shall vest and become exercisable (x) in twelve equal monthly installments beginning on June 30, 2017, or (y) on the date of our Annual Meeting, whichever comes first.

(11) Consists of 736,871 shares of common stock held by Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), and 298,786 shares of common stock held by VHCP Co-Investment Holdings II, LLC (“VHCP Co. II”). VHCP Management II, LLC (“VHCPM II”) is the sole general partner of VHCP II and the manager of VHCP Co. II and may be deemed to beneficially own these shares. Nimish Shah and Dr. Koh are members of VHCPM II and may be deemed to beneficially own the shares held by VHCP II and VHCP Co. II. Also includes shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 26,496 shares of common stock, 8,385 of which vest and become exercisable in 12 equal monthly installments beginning on March 10, 2016, and 18,111 of which vest and become exercisable with respect to one-third of the shares on February 10, 2017, and then in 24 equal monthly installments thereafter, and (ii) 2,454 shares of common stock granted on May 30, 2017, which shall vest and become exercisable (x) in twelve equal monthly installments beginning on June 30, 2017, or (y) on the date of our Annual Meeting, whichever comes first, all of which were granted to Dr. Koh for service on our Board of Directors. Dr. Koh is a member of VR Management, LLC (the “Management Company”). Under an agreement between Dr. Koh and the Management Company, Dr. Koh is deemed to hold the reported options for the sole benefit of the Management Company and must exercise the options solely upon the direction of the Management Company, which is entitled to the shares issued upon exercise. The Management Company may be deemed the indirect beneficial owner of the options, and Dr. Koh may be deemed the indirect beneficial owner of the options through his interest in the Management Company.

(12) Consists of 1,201,160 shares of common stock and 240,632 shares of common stock issuable upon the exercise of warrants held by PBM Capital Investments, LLC, 227,646 shares of common stock held directly by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship, 25,293 shares of common stock held by BKB Growth Investments, LLC and shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase (i) 26,496 shares of common stock, 8,385 of which vest and become exercisable in 12 equal monthly installments beginning on March 10, 2016, and 18,111 of which vest and become exercisable with respect to one-third of the shares on February 10, 2017, and then in 24 equal monthly installments thereafter, and (ii) 2,454 shares of common stock granted on May 30, 2017, which shall vest and become exercisable (x) in twelve equal monthly installments beginning on June 30, 2017, or (y) on the date of our Annual Meeting, whichever comes first, all of which were granted to Mr. Manning for service on our Board of Directors. Mr. Manning has the sole voting and investment power with respect to the shares held by PBM Capital Investments, LLC. Mr. Manning is co-manager of BKB Growth Investments, LLC and, as such, has unilateral voting and investment power with respect to the shares held by BKB.

(13) Consists of shares exercisable within 60 days of March 15, 2018 pursuant to options to purchase 2,454 shares of common stock granted on May 30, 2017, which shall vest and become exercisable (x) in twelve equal monthly installments beginning on June 30, 2017, or (y) on the date of our Annual Meeting, whichever comes first.

Equity Compensation Plan Information

The following table contains certain information with respect to our equity compensation plan in effect as of December 31, 2017.

	Shares of common stock to be issued	Weighted- average		Number of shares of common stock remaining available for future issuance under equity compensation plans
	upon exercise of	exercise price of		(excluding
	outstanding	outstanding		securities reflected in
Plan category	options (#)	options ($)		column (a)) (#)
Equity compensation plans approved by stockholders	3,243,371	$	41.30	2,204,082	(1)
Equity compensation plans not approved by stockholders	—	—		—
Total	3,243,371	$	41.30	2,204,082

(1) Reflects shares of common stock available for future issuance under our 2016 Plan at December 31, 2017. In January 2016, our board of directors adopted our 2016 Plan, which was approved by our stockholders in February 2016. The 2016 Plan became effective on February 10, 2016. Accordingly, no additional stock awards will be granted under the 2014 Plan. As of February 26, 2018 2,732,812 shares of common stock are available for issuance under our 2016 Plan.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

Related-Person Transactions Policy and Procedures

In February 2016, the Company adopted a written Related Person Transactions Policy that sets forth the Company’s policies and procedures regarding the identification, review, consideration and approval or ratification of “related-persons transactions.” For purposes of the Company’s policy only, a “related-person transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the Company and any “related person” are participants involving an amount that exceeds $120,000. Transactions involving compensation for services provided to the Company as an employee, director, consultant or similar capacity by a related person are not covered by this policy. A related person is any executive officer, director, or more than 5% stockholder of the Company, including any of their immediate family members, and any entity owned or controlled by such persons.

Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of the Board) for consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to the Company of the transaction and whether any alternative transactions were available. To identify related-person transactions in advance, the Company relies on information supplied by its executive officers, directors and certain significant stockholders. In considering related-person transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but not limited to (a) the risks, costs and benefits to the Company, (b) the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is

affiliated, (c) the terms of the transaction, (d) the availability of other sources for comparable services or products, and (e) the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. The policy requires that, in determining whether to approve, ratify or reject a related-person transaction, the Audit Committee consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, the best interests of the Company and its stockholders, as the Audit Committee determines in the good faith exercise of its discretion.

Certain Related-Person Transactions

Restricted Stock Purchase Agreement with Brian Kaspar

In January 2014, in connection with his consulting agreement, we entered into a restricted stock purchase agreement, or the RSPA, with Dr. Kaspar, pursuant to which Dr. Kaspar purchased 2,334,391 shares of our common stock at a price per share of $0.00007, for a total purchase price of $169.16. The grant date fair value of this award was $3.5 million. Such shares were initially subject to vesting over a four year period. However, in connection with the employment agreement entered into in January 2016, the unvested shares were vested in full. All of our obligations under the RSPA, other than the indemnity agreement described below, terminated on January 1, 2016 upon the effectiveness of Dr. Kaspar’s employment agreement.

Under the RSPA we have agreed to indemnify Dr. Kaspar against certain adverse tax events with respect to the shares of our common stock he purchased under the RSPA. Dr. Kaspar purchased the shares at a price of $0.00007 per share, which was the par value of the shares. Based on our estimate of the fair market value per share of our common stock as of the date of the RSPA of $1.51 per share, Dr. Kaspar purchased these shares at a discount of $1.5144 per share. Therefore, we estimate that we are contractually obligated to indemnify Dr. Kaspar for the tax and any related penalties he owes on the imputed income of $3.5 million, based on the difference between the fair market value of the restricted share grant and the purchase price paid. We estimate our total indemnity obligation will be approximately $4.5 million, including gross-up, interest and penalties. In 2017, we reimbursed Dr. Kaspar $1,792,706 for his amended United States Federal, State of Ohio and Ohio Regional Income Tax Agency, or RITA, filings as well as additional RITA penalties and interest owed for tax year 2014.

Our Relationships with Nationwide Children’s Hospital

Until September 2017, Dr. Brian Kaspar served as a principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. We are party to various agreements with Nationwide Children’s Hospital. Our payments to Nationwide Children’s Hospital in connection with these agreements totaled $380,000 in the aggregate in 2017 in connection with, among other things, initial and annual fees. Dr. Kaspar has an interest in certain of these payments.

Employment Agreements

We have entered into employment-related agreements with our executive officers. For more information regarding these agreements, see “Executive Compensation—Employment Agreements” and “Executive Compensation—Potential Payments Upon Termination or Change in Control.”

Employment of Dr. Allan Kaspar

Since July 2013, Sixeva, Inc., our former wholly-owned subsidiary, and beginning in January 2014, we have employed Dr. Allan Kaspar, the brother of Dr. Brian Kaspar. Dr. Allan Kaspar is currently our Vice President, Research and Development. In 2017, his compensation was $317,853. In addition, in 2017, we granted Dr. Allan Kaspar a stock option to purchase 8,300 shares of common stock, with a grant date fair value of $467,041.

Employment of Justine Gallup

Since August 2015, we have employed Justine Gallup, the sister-in-law of Sean Nolan. Ms. Gallup is currently our Office Manager and Human Resources Generalist. In 2017, her compensation was $136,280. In addition, in 2017, we granted Ms. Gallup a stock option to purchase 700 shares of common stock, with a grant date fair value of $39,389.

Indemnification

The Company provides indemnification for its directors and executive officers so that they will be free from undue concern about personal liability in connection with their service to the Company. Under the Company’s Bylaws, the Company is required to indemnify its directors and executive officers to the extent not prohibited under Delaware or other applicable law. The Company has also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that the Company will indemnify the officer or director, under the circumstances and to the extent provided for in the agreement, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and the Company’s Bylaws.

Director Independence

As required under the Nasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. The Board consults with the Company’s counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its current and former independent registered public accounting firms, the Board has affirmatively determined that the following six current directors are independent directors within the meaning of the applicable Nasdaq listing standards: Drs. Koh, Siffert and Verwiel and Messrs. Kearney, Manning and Welch. In making this determination, the Board found that none of these directors had a material or other disqualifying relationship with the Company.

In making those independence determinations, the Board took into account certain relationships and transactions that occurred in the ordinary course of business between the Company and entities with which some of its directors are or have been affiliated. The Board considered all relationships and transactions that occurred during any 12-month period within the last three fiscal years and determined that they were not relationships that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.

As provided in the Company’s Related Person Transactions Policy, the Board considered that the aggregate dollar amount of such transactions during any 12-month period within the last three fiscal years did not exceed the greater of $1 million or 2% of the other company’s consolidated gross revenues and, therefore, was not regarded as compromising the director’s independence. Based on this review, the Board affirmatively determined that all of the directors nominated for election at the Annual Meeting are independent under the standards set forth in the Company’s Corporate Governance Guidelines and applicable Nasdaq rules.

Item 14. Principal Accounting Fees and Services.

The following table represents aggregate fees billed to the Company for the fiscal years ended December 31, 2017 by Deloitte & Touche LLP, the Company’s principal accountant, and PricewaterhouseCoopers LLP, the Company’s former principal accountant, during the fiscal years ended December 31, 2016 and 2017.

	Fiscal Year Ended December 31,
	2017		2016
Audit Fees (1)
Deloitte & Touche LLP	$	937,136	$	0
PricewaterhouseCoopers LLP	345,800		1,113,900
Audit-related Fees (2)
Deloitte & Touche LLP	6,000		0
PricewaterhouseCoopers LLP	0		0
Tax Fees (3)
Deloitte & Touche LLP	40,000		0
PricewaterhouseCoopers LLP	0		0
All Other Fee (4)
Deloitte & Touche LLP			0
PricewaterhouseCoopers LLP	0		2,700
Total Fees	$	1,328,936	$	1,116,600

(1) Audit fees in 2017 and 2016 included fees for services associated with the annual audit of the financial statements, the review of the financial statements included in our quarterly reports on Form 10-Q and fees for services associated with other documents filed with the SEC, including our Registration Statements on Form S-3.

(2) Audit-related fees in 2017 represent the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit Fees.

(3) Tax fees in 2017 were principally for tax compliance, advice and planning.

(4) Other fees included licensing fees for use of certain accounting research and disclosure software.

All fees described above were pre-approved by the Audit Committee.

Pre-Approval Policies and Procedures

The Audit Committee has adopted a policy and procedures for the pre-approval of audit and, if applicable, non-audit services rendered by our independent registered public accounting firm. The policy provides that the Audit Committee must pre-approve specified services in the defined categories of audit services, audit-related services, and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee’s approval of the scope of the engagement of the independent registered public accounting firm or on an individual explicit case-by-case basis before the independent registered public accounting firm is engaged to provide each service. On a periodic basis, the independent registered public accounting firm reports to the Audit Committee on the status of actual costs for approved services against the approved amounts.

The Audit Committee has determined that the rendering of services other than audit services by Deloitte & Touche LLP is compatible with maintaining the principal accountant’s independence.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

Exhibit Index

Exhibit Number		Description of Exhibit
2.1		Agreement and Plan of Merger dated as of April 6, 2018, between the Registrant and Novartis AG and Novartis AM Merger Corporation (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on April 9, 2018).
3.1		Fifth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 17, 2016).
3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on February 17, 2016).
3.3		Amendment to the Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 9, 2018).
4.1		Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to the Registration Statement on Form S-1 filed on February 9, 2016).
4.2		Form of Warrant to purchase shares of Class B-2 Common Stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed on October 15, 2015).
10.1		Third Amended and Restated Investor Rights Agreement dated September 3, 2015 among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed on October 15, 2015).
10.1.1		Amendment, Waiver and Joinder to Third Amended and Restated Investor Rights Agreement, effective as of October 13, 2015, among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 10.1.1 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.2#		Amended and Restated 2014 Stock Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.3#		Form of Stock Incentive Award Agreement under 2014 Stock Plan, as amended to date (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.4#		Form of Exercise Notice and Agreement under 2014 Stock Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.5#		2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 filed on February 1, 2016).
10.6#		Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 filed on February 1, 2016).
10.7#		Non-Employee Directors’ Compensation Policy (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 filed on February 1, 2016).
10.8†		License Agreement dated March 21, 2014 between the Registrant and REGENXBIO Inc. (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.8.1†		First Amendment to License Agreement dated January 8, 2018 between the Registrant and REGENXBIO Inc.
10.9†		License Agreement dated May 29, 2015 between the Registrant and Asklepios BioPharmaceutical, Inc. (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.10†		Amended and Restated Exclusive License Agreement dated January 13, 2016 between the Registrant and Nationwide Children’s Hospital (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.11		Office Lease dated July 31, 2015 between the Registrant and Wanxiang Bannockburn, L.L.C. (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 filed on January 15, 2016).

10.11.1		First Amendment to Office Lease dated July 15, 2016 between the Registrant and Wanxiang Bannockburn, L.L.C. (incorporated by reference to Exhibit 10.1.1 to the Registration Statement on Form S-1 filed on August 24, 2016).
10.12		Form of Indemnification Agreement (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed on February 1, 2016).
10.13#		Employment Agreement dated June 8, 2015 between the Registrant and Sean Nolan (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.14#		Consulting Agreement dated January 28, 2014 between the Registrant and Brian K. Kaspar (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.15#		Restricted Stock Purchase Agreement dated January 28, 2014 between the Registrant and Brian K. Kaspar (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.16#		Employment Agreement dated January 1, 2016 by and between the Registrant and Brian K. Kaspar (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.17#		Employment Agreement dated July 24, 2015 by and between the Registrant and Thomas J. Dee (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.18#		Employment Agreement dated August 7, 2015 by and between the Registrant and Sukumar Nagendran (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 filed on January 15, 2016).
10.19†		Exclusive License Agreement dated September 9, 2016, by and between the Registrant and the Research Institute at Nationwide Children’s Hospital, with respect to Amyotrophic Lateral Sclerosis (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 filed on August 10, 2017).
10.20†		Exclusive License Agreement dated September 9, 2016, by and between the Registrant and Nationwide Children’s Hospital, with respect to Rett syndrome (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 filed on August 10, 2017).
10.21†		License Agreement dated June 7, 2017, by and between the Registrant and REGENXBIO Inc. (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 filed on August 10, 2017).
10.22#		Employment Agreement dated October 19, 2017 by and between the Registrant and Phillip B. Donenberg (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended September 30, 2017 filed on November 9, 2017).
10.23#		Employment Agreement dated February 26, 2018 by and between the Registrant and Sean Nolan (incorporated by reference to Exhibit 10.23 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
10.24#		Employment Agreement dated February 26, 2018 by and between the Registrant and Brian Kaspar (incorporated by reference to Exhibit 10.24 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
10.25#		Employment Agreement dated February 26, 2018 by and between the Registrant and Sukumar Nagendran (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
10.26#		Employment Agreement dated February 26, 2018 by and between the Registrant and James L’Italien (incorporated by reference to Exhibit 10.26 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
10.27#		Employment Agreement dated February 13. 2017 by and between the Registrant and Raken Modi.
16.1		Letter dated July 14, 2017 from PricewaterhouseCoopers LLP (incorporated by reference to Exhibit 16.1 to the Current Report on Form 8-K filed on July 14, 2017).
21.1		List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
23.1		Consent of Deloitte & Touche LLP (incorporated by reference to Exhibit 23.1 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
23.2		Consent of PricewaterhouseCoopers LLP (incorporated by reference to Exhibit 23.2 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).

31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.2 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
31.3		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.4		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Annual Report on Form 10-K for the period ended December 31, 2017 filed on February 28, 2018).
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

# Indicates management contract or compensatory plan.

† Confidential treatment has been granted for certain portions of this exhibit (indicated by asterisks). Such information has been omitted and was filed separately with the Securities and Exchange Commission.

* These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AVEXIS, INC.
	By:	/s/ SEAN P. NOLAN
		Sean P. Nolan President and Chief Executive Officer
	Date: April 30, 2018

AveXis, Inc. 10-K/A